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CHAPTER 1. Introduction
1.0 Source Material
Unless otherwise stated, the source material for sections 1.2-1.4 is a
combination of five sources: four reviews[31,156,173,174] and one textbook[75].
The reviews are especially well-written and offer timely snapshots of the pediatric
AML field and are highly recommended.
1.1 Purpose
Acute myeloid leukemia (AML) is a potentially devastating disease that
can affect people of all ages. While there are certain patient groups that typically
have favorable outcomes, AML carries a relatively poor prognosis for most age
groups when compared to other acute lymphoblastic leukemia (ALL).
Furthermore,

the

treatment

for

AML

typically

consists

of

rigorous

chemotherapeutic regimens and bone marrow/stem cell transplant, both of which
are associated with severe acute and chronic toxicity and the potential for
treatment-related mortality. In order to improve both survival and survivorship
after the diagnosis of AML, the development of better treatment options is of
paramount importance.
1.2 Hematopoiesis
Like other hematologic malignancies, AML is the result of unchecked
proliferation of immature cells from a hematopoietic lineage.

Hematopoiesis is

the lifelong process by which the cellular components of blood are produced. In
general, these components can be classified as either lymphoid (e.g. T- and Bcells) or myeloid (e.g. red blood cells [RBCs] and neutrophils), and each type of

2

cell plays a specific role within the body. For the sake of clarity, the traditional
dichotomous understanding of hematopoiesis will be presented here, although it
is important to note that this model has come under question in recent years[96].
1.2.1 Locations of hematopoiesis
As development progresses from embryo to adult, hematopoiesis occurs
at varying locations throughout the body. Initially, hematopoiesis begins in the
yolk sac of the developing embryo, and occurs exclusively at this site until the
development of the fetal liver. As the liver develops, it eventually is the home to
the majority of hematopoiesis, although there is a minor role for the fetal spleen
for a brief period.

Eventually, as the skeletal system and the marrow

compartment develop, hematopoiesis begins to occur primarily in red marrow.
Though there is a minor role for lymphatic organs in hematopoiesis later in life,
red marrow remains the primary site of hematopoiesis until death.
1.2.2 Lymphocytic hematopoiesis and the role of major lymphoid lineages
Though not the focus of the work presented herein, the lymphocytic
compartment is responsible for the majority of acquired immunity and cancer
prevention in humans, and until recently, deficiencies in this compartment were
largely incompatible with post-natal survival.

Derived from a common

hematopoietic stem cell (HSC), the lymphoid lineage produces T-cells, B-cells,
and natural killer (NK) cells. When a HSC is stimulated by the correct external
factors, which include extracellular signals from cytokines like notch-ligand and
certain interleukins, as well as internal factors, like expression of the proper
transcription factors, it develops into a common lymphoid progenitor. From this
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state, the decision is made, again by a combination of internal and external
factors, to differentiate into one of the terminal lymphoid lineages.
1.2.2.1 B-cells Antibody production, which is required for a rapidly acting
adaptive immune system, is the major responsibility of the B-cell lineage. Pre-B
cells migrate from the marrow to secondary lymphatic organs like the spleen or
lymph node, where they await further stimulation.

These cells then undergo

recombinatorial rearrangement of the B-cell receptor, which eventually forms the
scaffold for the variable region of an antibody. Upon antigen recognition, these
pre-B cells become mature B-cells, and can then differentiate into plasma cells
for antibody production, or memory B-cells which are long-lived cells that help to
preserve immunity.

Interrogation of B-cell development has led to great

advances in the understanding of DNA repair and cellular maturation processes,
however, in depth discussion of these processes is beyond the scope of this
work.
Of particular note is the somewhat unique case of plasma cell malignancy.
Multiple myeloma (MM) is a disease characterized by uncontrolled proliferation of
non-functional plasma cells. The natural history of this disease is quite different
from those of other hematologic malignancies, and unfortunately MM is usually
fatal.

Though not discussed specifically here, as MM is not diagnosed in

pediatric patients, good treatment overviews can be found in reviews by Stewart
et al. and Mehta et al.[130,194].
1.2.2.2 T-cells

Like B-cells, T-cell precursors migrate out of the bone

marrow to finish differentiation in a secondary location, in this case, the thymus.
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It is in the stroma of the thymus that the highly regulated process of T-cell
maturation occurs.

Though there are several subtypes of T-cells, the most

commonly discussed are those that express either CD4 or CD8. Helper T-cells,
or CD4+ cells, represent a variety of cells that act to enhance or reduce the
amount of immune activation in response to a stimulus. This compartment is
necessary for the full function of the acquired immune system, as CD4+ cells are
required for complete activation of CD8+ cytotoxic T-lymphocytes as well as
isotype switching in B-cells. In contrast, CD8+ cells, which at terminal maturation
become cytotoxic T-lymphocytes, are responsible for the recognition and
extermination of virally infected and otherwise transformed (including malignant)
cells.
1.2.2.3 Natural Killer Cells Occupying somewhat of a different role in the
lymphoid compartment are NK cells. The activation of and target recognition by
NK cells is a complicated matter, but the important feature of NK cells is that they
are able to target cells without prior exposure to an insult. These cells recognize
target cells through a combination of down-regulated major histocompatibility
complex I and antibody coating.

By recognizing these features, which are

common in virally infected and malignantly transformed cells, NK cells are able to
help clear potentially dangerous host cells.
1.2.3 Myeloid hematopoiesis – a general overview
The alternative to lymphocyte production is progression down the myeloid
lineage. At various stages, the presence of extracellular signaling molecules
(discussed in this section), stromal interactions, and transcription factor

5

expression (discussed in section1.3.2) all combine to drive progression towards a
specific lineage. The first major decision after myeloid commitment is whether or
not to produce granulocytes. If the granulocyte decision is made, development
will progress through the myeloblast stage culminating in either basophil,
eosinophil, neutrophil, or monocyte production.

The alternative to the

granulocyte pathway is the erythrocyte/megakaryocyte lineage, which will be
discussed in detail below in section 1.2.3.1.
Just as in lymphoid development, there is an important role for
extracellular signaling molecules in myeloid hematopoiesis and lineage
determination.

Important cytokines for myeloid differentiation include, among

others, interleukins 3, 4, and 5, stem cell factor (SCF), granulocyte-colony
stimulating factor, and granulocyte/macrophage-colony stimulating factor (G-CSF
and GM-CSF, respectively). These cytokines activate a variety of intracellular
pathways, but many bind receptor tyrosine kinases, with eventual activation of
the Janus-kinase/signal transducer and activator of transcription (Jak-STAT) and
mitogen-activated protein kinase (MAPK) pathways.

Though a detailed

description of these pathways is beyond the scope of this work, these commonly
activated pathways have pleiotropic effects, and can cause changes in
intracellular signaling cascades, protein localization, and transcription/protein
expression.
SCF serves as the ligand for the c-kit receptor, which is highly expressed
in most myeloid lineages as well as in many AML cases. Expression of c-kit, and
subsequent activation by its ligand, is required for hematopoiesis and survival.
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Though less commonly thought to be driving mutations in AML, mutations in c-kit
are in fact driving mutations for a type of tumor known as gastrointestinal stromal
tumor, or GIST. The colony-stimulating factors G-CSF and GM-CSF play a role
in lineage decision, and variations in their levels help drive production of specific
myeloid cells.
Another factor important for discussion here, due to its association with
malignant phenotypes, is the fms-like tyrosine kinase 3 (FLT3) ligand (FL). The
FLT3 receptor can be found on many hematopoietic cell types, and its activation
drives enhanced proliferation and survival. Interestingly, knockout of FLT3 is not
lethal, and administration of FL alone has little effect. However, FL appears to
substantially enhance the effect of many other cytokines.

Unfortunately, as

discussed below, aberrant activation of the FLT3 axis has deleterious effects.
1.2.3.1 Erythropoiesis and Thrombopoiesis

After the common myeloid

progenitor stage, cells have an opportunity to differentiate towards what is
referred to as a megakaryocyte-erythroid progenitor (MEP). At this point, though
there is some disagreement as to how, a cell has to determine which lineage to
pursue. In order to differentiate down the erythroid lineage, the master regulator
of erythropoiesis, GATA1, must be expressed. The product of the GATA1 gene
on the X chromosome, GATA1, is an essential transcription factor for the
development of the erythroid compartment.

The presence of GATA1 is an

absolute requirement for maturation of erythroid precursors and definitive (latestage) erythropoiesis, and mice that lack functional GATA1 protein die in utero of
severe anemia.

GATA1 binds and activates many genes important for
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erythropoiesis,

including

the

erythropoiesis-stimulating

growth

factor

erythropoietin (EPO). It does this, at least in part, in collaboration with another
transcription factor named “friend of GATA1” (FOG1). FOG1 interacts with the
N-terminus of GATA1 and enhances the transcription of genes. This interaction
is required for definitive erythropoiesis, but is not essential early in the erythroid
differentiation process.
Alternatively, the MEP can produce megakaryocytes, which are giant cells
that function to produce platelets. Like erythropoiesis, megakaryopoiesis also
requires fully functional GATA1 and FOG1 to progress to completion. Uniquely,
however, is the requirement for thrombopoietin (TPO), which is produced
constitutively in the liver and kidney. After binding the TPO receptor, intracellular
Jak-STAT signaling pathways are activated and serve to drive maturation and
eventual thrombopoiesis. Once sufficiently mature, megakaryocytes begin the
interesting process of endomitosis, in which the cell’s genetic material is
replicated and the cytoplasm size increases, but only the nucleus divides. This
process continues, and megakaryocytes with ploidy as high as 128N have been
reported. The motivations for maintaining such large amounts of genetic material
are slightly unclear, but it is thought that the additional DNA allows for more
effective transcription and subsequent maintenance of such large cells. Fully
mature megakaryocytes’ main function is the production of platelets, the function
of which will be discussed below.
1.2.4 Roles of mature myeloid cells
1.2.4.1 Red Blood Cells. The most prominent circulating myeloid cell is
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the erythrocyte, or red blood cell (RBC). They play the predominant role in the
transport of oxygen from the lungs to the deep tissues of the body, and are what
give blood its characteristic red color. These traits are both due to the presence
of iron-conjugated heme groups in hemoglobin – a heme containing protein that
is present in vast quantities in RBCs. While the absolute number of RBCs is
important for some disease states, it is the quantity of hemoglobin that is the
most useful clinically, because it is the most correlated with oxygen carrying
ability. In fact, anemia is typically defined by a lack of hemoglobin rather than a
low RBC count.
The RBC is unique in many ways among cells in the human body, most
notably for the lack of nuclei in mature cells. The absence of a nucleus prevents
the cell from being able to replenish proteins in response to stress, giving RBCs
a finite life span, which is typically on the order of 100 days in a healthy adult. As
the RBC ages, membrane changes allow the cell to be recognized by
macrophages in the liver, spleen, and lymph nodes, which phagocytose the cell,
clearing it from circulation.

This constant destruction requires active

replenishment, and as a result, RBCs are produced for the duration of a person’s
life. Of clinical importance is the detectability of recently produced RBCs in the
peripheral circulation.

These cells, which still possess varying degrees of

ribosomal RNA are termed reticulocytes, and can be identified by stains that can
detect the remaining RNA, such as methylene blue. As the cell matures further,
this RNA is eventually degraded, and thus RNA content can be used to judge the
age of the RBC. The quantity of circulating reticulocytes is a useful parameter to
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interrogate because it gives an index of how actively the bone marrow is
producing new RBCs, i.e., a high reticulocyte count indicates higher rates of
production. This has utility during chemotherapy treatment, because it helps an
oncologist to predict whether a patient’s hemoglobin will trend upward or
downward.
Clinically, and most relevant to this work, the most common problem
associated with RBCs is anemia, typically defined by low hemoglobin.

Low

hemoglobin reduces the ability to deliver oxygen to peripheral tissues, and can
be fatal in extreme cases. Anemia, when sufficiently acute and of substantial
magnitude, typically presents as decreased energy, and is common in cancer
patients receiving myelosuppressive chemotherapy.

Fortunately, anemia can

usually be managed (though not without potential complications) with infusion of
packed RBCs and appropriate dosing schedules.
1.2.4.2 Neutrophils

Often considered the first line of defense against

infection, neutrophils are the most common granulocytes and typically make up
the majority of circulating leukocytes. The role of neutrophils is to seek out and
destroy insults, as well as enhance inflammatory responses. Primarily directed
against invading bacteria, neutrophils are able to phagocytose bacteria and
attempt to kill the microorganism using highly reactive oxygen species in a
process that has been termed the “respiratory burst”.

The neutrophil also

releases several other pro-inflammatory cytokines that aid in the recruitment and
activation of other immune mediators. The pro-inflammatory nature of these cells
is offset at least partly by their short life span; neutrophils only live for a few days.
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Neutropenia, or low levels of neutrophils, can be a medical emergency
and is commonly seen in patients receiving myelosuppressive chemotherapy.
When patients’ neutrophil counts are depressed, their susceptibility to infection
skyrockets, and what are normally benign bacteria can become life-threatening.
Unfortunately, unlike RBCs, neutrophils cannot be transfused so the best
defense against profound neutropenia is prevention coupled with supportive care
(typically prophylaxis against bacterial infection with antibiotics and aggressive,
usually broad-spectrum antibiotic administration when infection is suspected).
Prevention has historically been achieved through optimization of dosing
regimens, careful monitoring of absolute neutrophil counts (ANC), and
administration of G-CSF (generic: filgrastim) to increase neutrophil production.
1.2.4.3 Other granulocytes

The remaining myeloid cell types, while

important in their own right, are mostly relevant to leukemia for the potential of
their lineages to become malignant.

Monocytes are large circulating

granulocytes that migrate to tissue and differentiate into various macrophage
subtypes. The principle role for these macrophages is phagocytosis of cellular
debris and invading pathogens. After phagocytosis, engulfed proteins are broken
down and presented for antigen recognition by the adaptive immune system.
Eosinophils are granulocytes that secrete pro-inflammatory markers as well as
proteins that help defend against certain parasites.

Basophils are the least

common form of circulating granulocyte, and function to secrete pro-inflammatory
markers involved in allergic responses. Lastly, mast-cells are very similar to
basophils, except they extravasate and take up residence in various tissues
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throughout the body. Malignant transformation of these last three lineages is
rare, but can be associated with poor outcomes and high symptomatic burden
[111].
1.2.4.4 Megakaryocytes and Platelets On the opposite end of the
spectrum from the small, anuclear RBCs are the megakaryocytes.

These

massive, multinuclear cells exist to produce platelets, which, like RBCs, lack
nuclei and serve somewhat as a delivery mechanism for their contents. Platelets
are extremely small cellular fragments that bud off of megakaryocytes (the exact
mechanism by which this occurs is somewhat unclear) and serve to maintain
hemostasis by providing the cellular components of the clotting cascade.
Though their lifespan is only on the order of one week, and typical counts are on
the order of 105/μL, a healthy individual can easily maintain platelet levels with
each megakaryocyte producing approximately 5,000 to 10,000 platelets over
their lifespan.

Like other cells of myeloid derivation, platelet levels can be

jeopardized by myelosuppressive chemotherapy. Because low platelet counts
prevent adequate clotting, hemodynamic instability is a major concern for
thrombocytopenia-inducing antileukemic interventions.

Fortunately, similar to

RBCs, platelets can be transfused; however their short life span and their high
cost dictate that this is only done when absolutely necessary.
1.3 Leukemia
Leukemia can be loosely defined as an aberrant hyperproliferation of
immature blood cells that do not form solid tumor masses (i.e. liquid cancer). In
general, leukemia can be either of the myeloid or lymphoid lineages, and
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classified as being acute or chronic in nature. Chronic leukemias tend to have
more mature cells, and are rare in pediatric patients. Acute leukemias, on the
other hand, are typically less mature and commonly occur in patients of all ages
and are potentially rapidly fatal if not readily treated; in fact, acute lymphoblastic
leukemia (ALL) is the most common childhood malignancy. Similar to AML, and
in some cases, on the same disease spectrum, are the myelodysplastic
syndromes (MDS).

These are a set of diseases that, while not always

considered malignant, can be deadly, are sometimes treated with chemotherapy
and often progress to AML. Though not discussed in this work, a good review of
MDS can be found in reviews by Stone and Fenaux & Adés[40,196]. This work
focuses on pediatric AML.
1.3.1 Epidemiology of Pediatric AML
Accounting for approximately 18% of childhood leukemia diagnoses, AML
is one of the more common childhood cancer diagnoses. The risk for developing
AML in the majority of cases is biological rather than environmental, with the only
established pediatric AML cause being in utero exposure to ionizing radiation.
Other exposures, e.g. maternal chemical exposure and parental age, have only
limited evidence supporting their association with AML. In America, the overall
incidence of pediatric AML is approximately 7.7 cases per million children. Race
appears to play only a very minor role in AML risk among Americans, with Asian
and Pacific Islanders having the highest incidence (8.4 per million) and African
Americans having the lowest risk (6.6 per million). The risk of childhood AML
peaks early in life at 18 per million in infants less than 1 year of age, reaches an
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incidence of approximately 4 per million in children aged 5-9. The factors that
convey the most risk are genetic. Down syndrome (DS) is the most common
genetic risk factor, however, less common diseases, especially those associated
with DNA repair deficiencies like Fanconi anemia and ataxia telangiectasia are
also associated with an elevated risk to develop pediatric AML. For a more
thorough overview of the epidemiology surrounding pediatric AML, please see
the 2013 review by Puumala[157].
1.3.2 Biology of Pediatric AML
Originally divided into only a few morphological subtypes, advancements
in molecular medicine have allowed for the reclassification of AML subtypes
based on the vast array of different morphological, cytogenetic, and genetic
variations that can be seen. One of the first major attempts at classification
came with the development of the French-American-British (FAB) system in
1976[10]. The FAB system divided AML into 8 different subtypes, M0-M7, which
correspond to: acute myeloblastic leukemia, minimally differentiated (M0); acute
myeloblastic leukemia, without maturation (M1); acute myeloblastic leukemia,
with granulocytic maturation (M2); acute promyelocytic leukemia (APL) (M3);
acute myelomonocytic leukemia (M4); acute monoblastic/monocytic leukemia
(M5a/b); acute erythrocytic leukemia (M6); acute megakaryocytic leukemia (M7,
AMKL).

Though less commonly used for prognostic indications, the FAB

classification is well-entrenched in modern hematology and is commonly referred
to in conjunction with the more modern World Health Organization (WHO)
classification.
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The WHO classification for myeloid neoplasms represents an attempt at
offering a comprehensive classification scheme based on all available clinical,
morphologic, cytochemical, immunophenotypic, and genetic data.

While

substantially more complicated than the older FAB systems, the WHO
classification (now in its 4th edition) allows for a much finer differentiation and
therefore is capable of offering more accurate prognostic correlations. The major
categories are: AML with recurrent genetic abnormalities; therapy related myeloid
neoplasms; myeloid proliferations related to Down syndrome; and AML not
otherwise specified, which then falls back on the older FAB system.

A full

discussion of this classification system is beyond the scope of this work, but a
2009 review of the changes performed by Vardiman et al.[210] covers many of
the important changes and is a good starting point for those with further interest.
Instead, some of the major subtypes with prognostic significance, and
significance to the work presented herein will be covered in more detail.
1.3.2.1 Core Binding Factor Leukemia Core binding factor (CBF) AML
describes a subset of leukemias that possess genetic alterations in one of the
two proteins that make up the family of protein complexes known as CBFs. A
heterodimer, CBF is a transcription factor that consists of DNA-binding α- and
non-DNA binding β-subunits. In AML, the α-subunit is encoded by the RUNX1
gene on chromosome 21, also known as AML1. The β-subunit is encoded by the
CBFβ gene on chromosome 16. The CBF transcription factor plays an important
role in normal hematopoiesis, and small perturbations of its expression or
function can have deleterious consequences, AML being just one (for a more
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comprehensive overview of CBF functions in hematologic physiology and
disease, see the 2002 review by Speck and Gilliland[190]).

Together, two

common cytogenetic abnormalities make up the largest group of CBF leukemias:
t(8;21)(q22;q22) and inv(16)(p13.1q22), representing approximately 15% and 6%
of pediatric AML cases, respectively. Despite these translocations both targeting
the CBF complex, each subtype has its own WHO classification, the prognostic
implications for which will be discussed below.
1.3.2.2 APL with PML-RARα fusion gene Somewhat unique among the
early FAB classifications was the M3 subgroup, which represents APL. As the
name suggests, most of the leukemic cells are abnormal promyelocytes, and in
most cases, many of the cells will have Auer rods. Though not pathognomonic
for APL, the presence of Auer rods, which are fused and typically elongated
granules, is easily detected by standard microscopic analyses. This is useful,
because it allows for a rapid narrowing of diagnoses which is important as newly
presented APL is a medical emergency. More so than other AML subtypes, APL
is associated with an extremely high rate of fatal hemorrhage.
Interestingly, almost every case (approximately 95%) of APL has a
characteristic t(15;17)(q22;q21) translocation which results in the fusion of the
PML and RARA genes. The PML gene product PML is important for nuclear
body formation and plays a role in transcriptional regulation and tumor
suppression. The RARA gene product, retinoic acid receptor alpha (RARα) is a
nuclear receptor that normally plays a role in a host of differentiation processes.
When these two genes fuse, the resultant protein prevents both of the
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physiologic functions. Instead, the PML-RARα fusion protein binds to DNA and
acts in a dominant negative fashion to repress gene expression as well as
nuclear body formation. This prevents further differentiation of the APL cell, and
while not sufficient, is considered necessary for the development of APL.
Though APL used to be almost universally fatal, this unique biology allows for the
use of targeted therapies (discussed below) that make APL one of AML subtypes
with a more favorable prognosis. In approximately 5% of cases, the RARA gene
is fused with another partner protein, resulting in variable changes to
chemotherapy sensitivity and prognosis. For more information, see the 2005
review by Zhou et al.[233].
1.3.2.3 Therapy-related myeloid neoplasms

In a departure from most

WHO classifications, myeloid neoplasms (both AML and MDS) that are believed
to be sequelae of previous therapy are grouped together into the same category
(tAML). Many types of cancer treatments act by inducing structural damage to
DNA (these mechanisms are discussed in depth in Chapter 3). In the process of
repairing this damage, it is possible that new genetic abnormalities may arise,
some of which may aid in the progression to AML. As this process takes time, in
many cases years, tAML is less common in children, mostly because by the time
tAML develops the patient has reached adulthood. However, tAML is a potential
consequence of many types of therapy, especially topoisomerase II poisons and
radiotherapy, both of which are commonly used to treat childhood malignancy.
Though tAML is not defined by any specific set of genetic abnormalities,
there are trends that arise. The use of certain chemotherapy drugs, especially
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anthracyclines and etoposide, are highly correlated with the development of
tAML with chromosomal abnormalities involving 11q23. At this locus is the MLL
gene (officially referred to as KMT2A) which encodes a histone methyltransferase.

Rearrangements at this site are common in infant AML, with

different fusion partners having different prognostic significance. However, in the
context of tAML, the presence of these commonly seen genetic abnormalities
help to differentiate tAML from de novo primary AML. The biology of tAML is
heterogeneous, but in general it is a difficult-to-treat disease for reasons that will
be discussed below.
1.3.2.4 FLT3-ITD AML FLT3 is a receptor tyrosine kinase encoded by the
FLT3 gene on chromosome 13. As mentioned above, FLT3 plays an important
role in normal hematopoiesis. Like other receptor tyrosine kinases, FLT3 exists
primarily

as

a

monomer

that

upon

ligand

binding

dimerizes

and

autophosphorylates. This activates an intracellular signaling cascade that has
consequences for maturation and proliferation.

In approximately 10-20% of

pediatric AML cases, an internal tandem duplication of variable length (FLT3ITD) in exons 14 and 15 promotes ligand-independent activation of FLT3. The
unfortunate consequence of this activation is decreased maturation and
increased proliferation of myeloid progenitor cells. Similar to FLT3-ITD are point
mutations in FLT3 that have similar effects, though these mutations are less
common. Because FLT3-ITD is not mutually exclusive with other AML subtypes,
but is instead an additional abnormality, AML FLT3-ITD does not get an
independent WHO classification.

However, FLT3-ITD status has important
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prognostic and therapeutic implications and is therefore interrogated as part of
standard diagnostic workups. For more information, see the review by Stirewalt
and Radich [195].
1.3.2.5 AML with CEPBA mutation The CCAAT enhancer binding protein
family (C/EBP) is made up of several related transcription factors, the α-isoform
of which (C/EBPα) is commonly mutated in pediatric AML. These proteins play
an important role in the differentiation of many tissue types. Specifically, C/EBPα
is heavily involved in the maturation of the granulocyte lineage, binding to the
promoters and supporting transcription of a variety of genes necessary for this
process.

Mutations in the CEBPA gene in the context of AML result in the

expression of a 30 kDa form of the C/EBPα protein (full length is approximately
42 kDa) which functions in a dominant negative fashion to prevent appropriate
promoter binding and gene transactivation. Further information can be found in
the 2009 review by Ho et al.[73].
1.3.2.6 AML with NP1 mutation Nucleophosmin, or NPM1, the protein
encoded by the NPM1 gene, has pleiotropic functions, but is most known for its
role as a nuclear chaperone that is involved in the import and export of a wide
variety of substrates. When mutated, these functions typically cease, and many
cellular processes go into disarray. Mutations in NPM1 are relatively uncommon
in pediatric AML (up to approximately 10%, 20% in cytogenetically normal AML
[CN-AML]), however their prevalence increases with patient age. Importantly for
AML, NPM1 is involved in hematopoiesis, DNA replication and repair, as well as
gene transcription.

When mutated, these functions are affected to varying
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degrees, and NPM1 mutations are considered to be primary events in the
development of malignancy in some cases.[76,112]
1.3.2.7 Myeloid proliferations related to Down Syndrome Down syndrome
is a commonly occurring genetic abnormality characterized by constitutional
presence of trisomy 21. DS is associated with a host of developmental and
health problems, including a substantially increased risk of developing leukemia.
The characteristics of DS and associated AML will be discussed in depth in
section 1.5.
1.4 Treatment and Prognostic Considerations for Pediatric AML
When treating AML, there are many factors that need to be considered.
The first is urgency; AML, especially with certain presentations, is a medical
emergency that requires immediate intervention. The second is efficacy; not all
interventions are equally effective against each disease subtype.
complicating efficacy, is toxicity.

Finally,

Though advances have been made in the

treatment of pediatric AML, the most effective therapies are profoundly toxic even
when administered properly. Therefore, it is imperative that measures be taken
to maximize efficacy and minimize toxicity.

Fortunately, years of experience

have provided many effective treatment protocols, most of which build on a
framework of induction, consolidation, and, when necessary, salvage and
transplant.
1.4.1 Overview
When a patient first presents with AML, it is important to reduce their
leukemic burden. Acute leukemia causes morbidity for a variety of reasons, but
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some of the most severe are a direct result of the high burden of rapidly
proliferating leukemic blasts. Extremely high white blood cell (WBC) counts, or
hyperleukocytosis (commonly defined as a WBC count > 100,000 cells/μL), are
associated with problems directly resulting from the high cellularity of the blood.
When symptomatic, the condition is called leukostasis.

There are many

pathologies that contribute to the symptomology of leukostasis, but one of the
most important is the potentially occlusive nature of the condition. As a result of
the high viscosity caused by the relatively rigid circulating blasts, small vessels
may become occluded by aggregates of WBCs. This can result in symptoms
similar to stroke or pulmonary embolism, including respiratory distress and focal
or generalized neurological deficits. Other problems at presentation can be bone
pain, which is believed to be the result of increased pressure in the marrow
cavities of long bones resulting from hyperproliferation of blasts, and cytopenias.
As proliferating blasts can overwhelm marrow cavities, it is possible that
physiologic hematopoiesis is prevented, resulting in deficiencies in other
compartments. Common manifestations that result in a patient seeking medical
care are anemia, which usually presents as fatigue, and thrombocytopenia,
which usually presents as uncontrollable bleeding or easy bruising. Alternatively,
neutropenia can result in severe infection.
In order to rapidly decrease the leukemic burden, the patient is treated
with what is referred to as induction chemotherapy. Typically given in multiple
rounds, induction chemotherapy typically consists of moderately high intensity
dosing schedules. The goal with induction chemotherapy is to safely induce
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what is referred to as remission, or undetectable disease (see discussion on
minimal residual disease [MRD] in section 1.4.3.4), and to allow some restoration
of normal hematopoiesis. A patient with newly diagnosed AML is typically very
ill, and may be less able to tolerate maximal dose chemotherapy, so care must
be taken to ensure patient safety.
Once remission is achieved, therapy transitions to a phase known as
consolidation.

Consolidation therapy is usually maximally intense, both with

regard to dosing (high doses) and timing (short latency between doses). The
goal of consolidation is to eliminate any remaining leukemic blasts, ideally
resulting in a cure.

Both the duration and types of treatments used for

consolidation vary between AML subtypes.
In the event that a patient’s disease does not respond to treatment, and a
remission cannot be achieved, their disease is considered primary refractory.
Therapy directed at inducing a remission in refractory disease is often referred to
as salvage therapy.

Highly variable depending on subtype, salvage therapy

often consists of somewhat experimental treatments, or treatments that are
associated with unfavorable side effect profiles that are preferably avoided.
Similarly, if a patient’s disease that was once in remission returns, it is
considered to be relapsed. Relapse, for many AML subtypes, is not uncommon,
and is associated with varying prognoses. In the event of relapse, re-induction is
attempted.

If unsuccessful, the disease is considered secondary refractory.

When chemotherapy alone is likely to be insufficient to achieve a cure,
hematopoietic stem cell transplant (HSCT), or bone marrow transplant, may be
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pursued.
1.4.2 Prognosis
In the past, AML was associated with an almost 100% mortality rate.
Fortunately, with the discovery of new drugs and improvements in supportive
care, survival among pediatric AML patients as a group has risen to
approximately 70%. With greater treatment experience and understanding of the
biology underlying AML has come the ability to identify patients that have higherand lower-risk disease.

This has allowed for the use of less aggressive

treatment in those patients with more favorable prognoses, saving them
unnecessary toxicity, while still giving appropriate therapies to those whose
prognoses are more guarded.
1.4.2.1 Favorable Prognostic Indicators

There are several disease

characteristics that are associated with a favorable prognosis (survival >70%).
Fortunately, CBF AML (t(8;21), t(16;16); inv(16)), which represents one of the
largest AML subgroups, is associated with a favorable prognosis. Similarly, APL
with the standard t(15;17) cytogenetics is also associated with good outcomes.
Mutations in C/EBPα or NP1 are also positive findings, so long as there is not
concurrent Flt3 mutation or ITD. Finally, AML in the DS population is associated
with one of the most favorable prognoses.
1.4.2.2 Adverse Prognostic Indicators In contrast to those findings listed
above, there are several cytogenetic or genetic abnormalities associated with
poorer

outcomes

t(10;11)(p12;q23),

(survival

<50%).

t(6;9)(p23;q34),

Certain

translocations,

inv(3)(q21126.2),

including

t(3;3)(q21;q26.2),
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t(7;12)(q36;p13), t(7;12)(q32;p13), and t(5;11)(q35;p15.5) are poor prognostic
markers. Fortunately, these are less common findings. Though not a specific
finding, tAML is always considered to have an adverse prognosis.
mutations in Flt3 or Flt3-ITD are less favorable.
abnormalities carry an adverse prognosis.

Finally,

When found alone, Flt3

In combination with other, more

favorable abnormalities, the net result may be intermediate risk, but Flt3
abnormalities are never favorable prognostic findings.
1.3.2.3 Intermediate risk

For many subtypes of AML, prognosis is

considered to be intermediate (survival 50-70%). In some cases, this could be
the result of underlying biology, but often assignment of intermediate risk is due
to inconclusive results regarding outcome for that specific subtype. There are
many findings that have had variable outcomes between trials, and therefore it is
up to the clinician’s judgment to assign risk and subsequent treatment strategy.
1.4.3 Treatment of Pediatric AML
Though there are many variations on standard treatment for AML, an in
depth discussion of these variations and their rationale is largely beyond the
scope of this work. However, it is important to consider the standards of care
when investigating new potential therapies, as any interventions will likely be
given in the context of said therapies or after they have failed.
1.4.3.1 Standard Induction and Consolidation Standard induction therapy
for pediatric AML has remained largely unchanged for over 20 years, and
consists of a “3+7” or “3+10” strategy of administering cytarabine (araC) and an
anthracycline (or substitute), typically daunorubicin (DNR). Both araC and DNR
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are genotoxic agents that non-specifically target replicating cells. An in-depth
discussion of their mechanisms of action and associated toxicities can be found
in Chapter 3, but the major toxicities associated with their use can be considered
to be myelosuppression (araC) and late cardiac toxicity (DNR). In the typical
administration schedule, DNR is given at a dose of 45-60 mg/m2 for three days
and araC is given at a dose of 100-200 mg/m2 for 7 or 10 days, either twice daily
or via continuous infusion.

This induction can be repeated depending on

protocol. Most protocols include a third drug for induction, often etoposide or
thioguanine. The evidence supporting these inclusions is, for the most part, nonconclusive with regards to benefit to overall survival (OS). If complete remission
(CR) is obtained, consolidation therapy is appropriate.
Consolidation therapy typically consists of high intensity variants of what
was used during induction. For most cases, at least two rounds of high-dose
araC (HiDAC) are given. The HiDAC course typically consists of several doses
of araC usually in the range of 1-3 g/m2, usually given every 12 hours for a total
of <10 doses. Some protocols treat for 3 consecutive days, while others spread
out the doses.
clinical findings.

In many protocols, dosage is determined at least in part by
For most AML subtypes, post-consolidation maintenance

therapy is inappropriate.
Part of every standard therapy protocol should be the administration of
intrathecal chemotherapy. Though central nervous system (CNS) involvement is
uncommon, and CNS relapse does not affect every patient, there is good
evidence to suggest that administration of intrathecal chemotherapy to every

25

patient greatly reduces the occurrence of these unfavorable events. Though
there is a dearth of data suggesting the appropriate intrathecal treatment
regimen, a combination of methotrexate, araC, and hydrocortisone is considered
to be likely ideal, and typically between 4 and 12 treatments are given. It is,
however, agreed upon that CNS irradiation is inappropriate despite being
effective, and should not be used in lieu of chemotherapy.
1.4.3.2 Role of HSCT The use of HSCT in the treatment of pediatric AML
is, in many cases, controversial. Although HSCT is often considered to be a
curative therapy, the profound toxicity associated with the procedure prevents its
use for low-risk disease.

The benefit of HSCT is that the combination of

extreme-intensity condition regimens and graft-vs-tumor effects are highly
effective at eradicating disease. However, the potential for graft-vs-host disease,
the massive supportive care burden, and risk of mortality associated with HSCT
are of serious concern.

One of the earliest hurdles that HSCT faces is the

identification of a suitable donor. Typically, the ideal donor is an HLA-matched
sibling, although frequently unrelated donors are required. Prior to transplant, a
conditioning

regimen

of

either

total

body

chemotherapy is undergone by the patient.

irradiation

or

myeloablative

After conditioning, the cells are

infused into the patient, but marrow reconstitution can take weeks, assuming
successful engraftment. Current recommendations do not allow for HSCT in first
CR for low-risk patients, but for other patients a risk-benefit analysis is
appropriate. Although there has been demonstrated benefit to HSCT for high
risk patients, treatment related mortality for HSCT in pediatric AML patients is as
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high as 41%[16].
1.4.3.3 Treatment of APL and Flt3-ITD AML Both APL and Flt3-ITD AML
present opportunities for treatment with agents that are not commonly used for
other subtypes of AML. For the treatment of APL, the use of all-trans retinoic
acid (ATRA) is the standard of care. When exposed to ATRA, the PML-RARα
fusion protein relocalizes and transcription of differentiation-inducing genes is
increased. The use of ATRA has helped change APL from being one of the most
fatal subtypes of AML to one of the most curable. For the case of Flt3-ITD AML,
treatment with the multiple tyrosine kinase inhibitor sorafenib offers potential
benefit. Early studies have shown favorable results, although the development of
resistance and cross-resistance to other inhibitors remains problematic[78,219].
1.4.3.4 Role of MRD Monitoring At specific stages of treatment, it is
important to measure the response to treatment. Historically, this was performed
by morphological analysis of bone marrow biopsies/aspirations. Unfortunately,
this method is very subjective and offers poor sensitivity for detection of leukemic
blasts, and MRD negativity was considered <1/50 cells.

However, recent

advances have allowed for more sensitive and objective methods for the
detection of residual disease. In the event that a specific fusion gene or other
genetic abnormality are identified, PCR detection can be used with a sensitivity
of approximately 1/10,000 cells.
multiparameter flow cytometry.

More useful for most cases, though, is
By identifying a patient-specific cell surface

marker profile, it is possible to rapidly identify as few as 1/1000 cells as leukemic
blasts for most patients. The utility of this approach was demonstrated to great
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effect in the St. Jude AML02 trial, as well as the recent COG-AAML0431 trial.
[29,175,188,212]
1.5 Down Syndrome
Down syndrome, originally described by John Langdon Down in the latter
half of the nineteenth century, is a genetic disorder with a host of manifestations.
Although an in-depth characterization of the health problems and implications for
care of individuals with DS is beyond the scope of this dissertation, the
heightened incidence and associated biological mechanisms of AML in this
population are of great interest and are highly relevant to the presented work.
1.5.0 Source Material
Unless otherwise stated, most of the general background information
presented below was derived from two excellent overviews of DS ([170,216])
1.5.1 Genetics and Incidence of DS
In order to conclusively diagnose a patient with DS, their cells must be
trisomic for chromosome 21.

Though there are less common mechanisms

leading to trisomy, such as translocations or mosaicism, most cases of DS are
the result of non-disjunction events at meiosis I of the maternal gamete. In the
United States, the incidence of DS in live births is approximately 1 in 1,000.
Incidence in other countries varies, largely as a result of elective termination of
prenatally diagnosed pregnancies. The only well-established risk factor for DS is
advanced maternal age, as nondisjunction events occur at higher frequencies as
women age [67]. That being said, there have been efforts to identify modifiable
risk factors such as folate supplementation [77], although they have been largely
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met with limited success.
1.5.2 Health concerns in individuals with DS
As mentioned above, individuals with DS are at an elevated risk for a large
variety of health problems. The most pervasive concerns in DS patients are
neurocognitive and psychiatric in nature. Individuals with DS typically suffer mild
to moderate cognitive impairment, reaching maximum cognitive ability around
adolescence. The difficulties associated with cognitive impairment are frequently
compounded by psychiatric problems such as attention-deficit hyperactivity
disorder and depression. As a result, children with DS need special care that
can persist well into adulthood, and in some cases the requirement is life-long,
with only few individuals capable of truly independent living. Other contributing
factors to the cognitively impaired phenotype are common anatomical
abnormalities that inhibit communication abilities. Individuals with DS commonly
have structural differences in the systems involved in speech and hearing, such
as macroglossia and Eustachian tube abnormalities or other conductive
deficiencies. These need to be identified early, as difficulties in communication
can compound the otherwise present cognitive disability. Additionally, a large
portion of DS patients have hypothyroidism, which if left untreated can lead to
further cognitive impairment.
There are several commonly encountered health problems in the DS
population that are especially concerning in the context of leukemia treatment.
Approximately half of pediatric DS patients have congenital heart defects (CHD)
of varying severity.

Although not all CHDs require surgical intervention, the
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already decreased cardiac function at least theoretically puts DS children at an
increased risk of cardiac dysfunction if treated with cardiotoxic chemotherapy
regimens.

Another concern results from a combination of anatomical and

immunological abnormalities that result in an increased risk of infection.
Structural differences in the both the upper and lower airways of DS patients put
them at a higher baseline risk for infection. This is in addition to a lower baseline
immune function in DS patients. Though there have not been any individual
causes of the lowered immune function, it is known that DS patients have belowaverage levels of both T- and B-cells.
Finally, DS patients have an unusual risk profile for both solid tumors and
Alzheimer’s disease, though these diseases are of little significance for the
pediatric DS population. With the exception of testicular cancer and pediatric
leukemias, DS patients have lower than expected incidence and mortality rates
for cancer [66,147,198]. Conversely, the prevalence of Alzheimer’s disease (AD)
in older DS patients is exceptionally high. As the life expectancy for individuals
with DS has increased (median survival is approximately 60 years), so has the
incidence of diseases that appear later in life, such as AD, which is estimated to
affect as many as 60% of elderly DS patients [235].
1.5.3 Leukemia and DS
Despite having a lower incidence of solid tumors, the total incidence of
cancer in the DS population is similar to that in the non-DS population due to the
increased susceptibility for developing leukemia.

Interestingly, this unusually

high risk for leukemia is only present in the pediatric DS population and applies
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to both ALL and AML. In fact, in a 2005 study, it was found that DS patients
represented approximately 2% of ALL cases and 14% of AML cases, giving DS
children an approximately 50-fold greater risk of developing leukemia by age
5[230].
Although this work focuses on AML, it is important to acknowledge the
unique features of ALL in the DS population.

Unlike non-DS pediatric ALL

patients, who typically have OS of approximately 80-90%, DS-ALL patients have
less favorable outcomes (OS approximately 70%). Their disease also is very
different from that in the non-DS population in that commonly seen genetic
abnormalities are rare and almost every DS-ALL case is of the B-precursor cell
classification, with almost no cases having a T-cell phenotype.

An excellent

concise review of current DS-ALL treatment and biology can be found in the
2014 article by Izraeli et al. [89].
1.5.3.1 AML in the Pediatric DS Population In contrast to the non-DS
population, AML in the DS population is associated with many unique features.
DS-AML patients are typically younger than non-DS AML patients, with most
cases presenting in patients less than four years of age.

Furthermore,

depending on the study, as many as 100% of pediatric DS-AML patients have a
megakaryocytic

phenotype

[3,30,45,101,106,161,163,164,175,230,236].

(FAB

M7,

AMKL)

In fact, DS patients have an

estimated 500-fold increased risk for developing AMKL compared to non-DS
children [236]. This phenotype is almost universally associated with a somatic
mutation in the second exon of the GATA1 gene, the significance of which will be
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discussed below. Interestingly, GATA1 mutations are found almost exclusively in
DS-AMKL blasts, with only rare exceptions [2,71,204,215].

Finally, DS-AML

patients enjoy better prognoses than their non-DS counterparts, with OS of
approximately 80-90% [3,30,45,101,106,161,163,164,175,230,236].
1.5.3.2 Leukemogenesis in DS-AML Unless otherwise stated, this section
represents a condensation of information obtained from references [2,13,2426,32,71,110,124,172,185,187,204,207,215]. Underlying the features common
to DS-AML is one of the better understood mechanisms of stepwise
leukemogenesis.

Likely contributing to both ALL and AML is the effect that

constitutional trisomy 21 exerts on fetal liver hematopoiesis. The presence of
several genes localized to chromosome 21, as well as what is most likely a
number of currently unknown factors, alters the population distribution and
growth rates of various hematopoietic progenitors in the fetal liver.

Importantly

for DS-AML, trisomy 21 appears to give a growth advantage to MEPs, which are
both more frequent and clonogenic than in non-DS controls. At this stage, it is
possible for a cell to develop a mutation in the GATA1 gene, which typically
causes the transcription of a shorter GATA1s protein, as the result of either
alternate splicing or transcription start-site utilization.

Lacking the N-terminal

transactivation domain, but still able to interact with FOG-1, GATA1s prevents
erythroid differentiation, while also rendering the cell unable to complete
megakaryocytic differentiation. The combination of GATA1s and the background
of trisomy 21 is sufficient to drive a hyper-proliferation of immature
megakaryoblasts.
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The unchecked proliferation on immature megakaryoblasts in the fetus
can have disastrous complications, occasionally presenting as hydrops fetalis.
More often, however, this proliferation spontaneously resolves either pre- or
postnatally.

If detected in an infant, this condition is termed (among other

names) transient myeloproliferative disorder (TMD).

Whether TMD resolves

spontaneously or requires treatment (see below), there is a chance that it may
progress to AMKL. Interestingly, it has recently been conclusively shown that
AMKL clones are derived from TMD cells, and that they possess similar
mutational spectra, albeit at a slightly higher mutational frequency (mean 5.8
non-silent mutations in AML vs. 1.7 for TMD) [136,229]
1.5.3.2 Treatment concerns in DS-AML and TMD As its name implies,
TMD is often transient and resolves spontaneously in the majority of cases. This
spontaneous resolution has made estimations of incidence difficult, as it has
been expected that many cases are clinically silent. A recent study found that,
surprisingly, almost every DS neonate had circulating blasts, but only
approximately 20% had detectable GATA1 mutations, indicating TMD[169]. In
addition to the approximately 20% of TMD patients that progress to AMKL, TMD
itself is associated with potential complications and may require treatment.
These typically result from either hyperleukocytosis or organ infiltration by blasts,
with pancytopenia and hepatic fibrosis being common signs. In the event of
symptomatic or complicated disease, low-dose cytarabine may be indicated (13.5 mg/kg/day for 5-7 days)[44]. Overall, TMD is associated with a mortality of
approximately 20%.
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As mentioned above, DS-AML is associated with a favorable prognosis
when compared to non-DS AML. For reasons that will be discussed in Chapter 3
of this work, DS-AML cells are known to be more sensitive to chemotherapy;
however, this is at least partially offset by an increase in sensitivity of nonleukemia cells in DS patients. As a result, DS-AML is often successfully treated
with lower intensity chemotherapy regimens. For example, the recently finished
COG AAML043 trial, which focused exclusively on DS-AML, utilized a cumulative
araC dose of 27,100 mg/m2 araC (Dr. Jeffrey Taub, personal communication),
whereas the cumulative araC dose for the St. Jude AML02 trial for non-DS AML
was 45,600 mg/m2 [175].

Though outcomes are generally favorable, those

patients who either have refractory disease or suffer a relapse have few options
and poor survival of approximately 25% [119,120,199].

Further complicating

matters is the poor survival after HSCT, which is only approximately 19% in the
DS-AML patients [72]. Therefore, advances in care are necessary to better treat
this group of patients.
1.6 Why study pediatric DS-AML?
It is not difficult to make a Utilitarian argument against research directed at
improving outcomes for relatively uncommon diseases like DS-AML, or pediatric
cancers in general.

Though a thorough discussion on the philosophical

considerations of such research is well beyond the scope of this work, a good
discussion of the considerations for orphan diseases (which are in many ways
similar) can be found in the 2005 paper by Gericke, Riesberg, and Busse[54].
Briefly, it is a fairly commonly held belief that there exists a moral obligation to
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help every population, regardless of frequency or perceived value to society.
Furthermore, while gains in overall survival after cancer diagnosis have been
modest at best, certain subgroups, like those with pediatric cancers, have
benefited greatly. For example, 5 year survival after diagnosis with pediatric
AML has increased from only 19% in 1975 to over 60% today [189]. Moreover,
the study of relatively rare diseases that affect relatively homogenous
populations or result from common genetic alterations has guided our
understanding of some of the most important physiologic and pathological
processes that are present in the entire population. Therefore, it is the belief of
this author that there is merit in studying pediatric AML, especially in the DS
population, not only for the benefit it may provide to those individuals, but also to
the population at large. Finally, the NIH has also developed a plan (available at
downsydrome.nih.gov) to ensure that adequate research resources are directed
for DS individuals, a vulnerable patient population due to their multiple medical
problems.
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CHAPTER 2 - Overexpression of GATA1 Confers Resistance to
Chemotherapy in Acute Megakaryocytic Leukemia
2.0 Preface
This chapter is taken from a previously published work with the same title
published in 2013 (PMID 23874683) [18]. It represents a project taken over by
this author upon joining the lab. As such, much of the work was done by other
lab members, including the microarray and ChIP-on-Chip analyses and the work
leading up to those experiments. This author was responsible for generation of
the over-expression clones, validation of the array based experiments, back-end
analysis of array data, and composing the manuscript. The figure numbers have
been adjusted to incorporate what was a supplemental figure in the original
manuscript.

Finally, the supplemental tables associated with the original

publication have been omitted from this dissertation as they are especially
cumbersome and are supplemental in nature. They can be found on PLoS One’s
website.
2.1 Introduction
In the pediatric population, acute myeloid leukemia has a relatively
guarded prognosis with five-year survival rates of approximately 50%
(www.seer.cancer.gov),

despite

intensive

therapy.

Acute

megakaryocytic

leukemia (AMKL; M7) is a biologically heterogeneous form of AML, representing
~10% of pediatric AML cases and 1-2% of adult AML cases [47,166]. AMKL is
considered a very high-risk subgroup with event-free survival (EFS) rates of
<35% [5,140]. Remarkably, Down syndrome children with AML, and in particular,
AMKL, have extremely high EFS rates of approximately 80% [5,45,106,163,236].

36

The blast cells of DS AMKL patients almost universally harbor a somatic
mutation in exon 2 of the transcription factor GATA1 gene (localized to Xp11.23),
resulting in the introduction of premature stop codons and the synthesis of a
shorter GATA1 protein (designated GATA1s, 40-kDa) initiated from a
downstream initiation site and distinguishable from the wild-type GATA1 (50-kDa)
[215].

Both GATA1s and the wild-type GATA1 proteins show similar DNA

binding abilities and interact with a partner protein named “friend of GATA1”
(FOG1), though the GATA1s protein exhibits altered transactivation capacity due
to the loss of the N-terminal activation domain [215].
GATA1 is a zinc finger transcription factor that is essential for
hematopoiesis of the erythrocyte/megakaryocyte lineages. GATA1 acts as an
activator or repressor of different target genes by forming distinct activating or
repressive complexes with its partner proteins (reviewed in [32]). The
pronounced differences in clinical outcomes between DS and non-DS AMKL
patients and differences in the GATA1 gene mutation status in blast cells suggest
a potential role for GATA1 in chemotherapy response in both DS and non-DS
AMKL cases. In the non-DS population, overexpression of GATA1 in
megakaryoblasts from children with AMKL compared to blasts from children with
other subtypes of AML was previously observed in gene expression microarray
studies [171]. Further, earlier studies demonstrated a worse prognosis for AML
patients (adults without AMKL) whose blast cells expressed higher levels of
GATA1 than patients whose blasts expressed lower levels of GATA1 [6,186].
Collectively, these studies suggest that GATA1 may contribute to chemotherapy
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resistance via regulation of GATA1 target genes in AML, especially in the AMKL
subtype.
Bcl-xL, encoded by the long form splice variant of Bcl-x transcripts which
counteracts apoptotic signals, may be one of these GATA1 target genes. Bcl-xL
is a Bcl-2 family protein that is abundantly expressed in both megakaryocytes
and erythrocytes (reviewed in [145]). Bcl-xL deficient mice exhibit massive
apoptosis of fetal liver hematopoietic cells, suggesting that Bcl-xL prevents
apoptosis of hematopoietic cells [133]. Previous studies have established that
GATA1 and erythropoietin cooperate to promote erythroid cell survival by
regulating Bcl-xL expression [58], and that GATA1 is capable of binding and
activating the Bcl-xL promoter during erythroid differentiation [104]. Thus, it is
conceivable that GATA1 may also regulate Bcl-xL in megakaryocytes as
megakaryocytes and erythrocytes are derived from a common progenitor and
both Bcl-xL and GATA1 are expressed in megakaryocytes.
In this study, we confirmed the overexpression of GATA1 transcripts in
non-DS

megakaryoblasts

compared

to

non-DS

AML

blasts.

We

also

demonstrated that GATA1 plays critical roles in sensitivities of megakaryocytic
cells to cytarabine (ara-C) and daunorubicin (DNR), the two main drugs used for
treating AML, through direct regulation of Bcl-xL. Furthermore, we found that the
histone deacetylase (HDAC) inhibitor, valproic acid (VPA), can decrease GATA1
expression and synergize with ara-C in exerting antileukemic activities toward
megakaryocytic leukemia cells. Using gene-expression microarray and ChIP-on-
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Chip analyses, we identified additional GATA1 target genes which may be
downstream targets for AMKL treatment.
2.2 Materials and Methods
2.2.1 Clinical Samples
Diagnostic AML blasts (including blasts with the AMKL phenotype) were
obtained from the Children's Hospital of Michigan leukemia cell bank and from
the Pediatric Oncology Group 9421 study, as previously described [202]. The
diagnosis of AMKL was confirmed by flow cytometry detection of the
megakaryocytic antigens CD41 and CD61. Mononuclear cells were isolated on
Ficoll-Hypaque gradients to obtain highly purified mononuclear cell fractions
consisting mostly of leukemic blasts. Written informed consent was provided by
the parent or legal guardian of the patient according to the Declaration of
Helsinki. The research protocol was approved by the Human Investigation
Committee of Wayne State University School of Medicine.
2.2.2 Cell Culture and Chemotherapy Agents
The Meg-01 megakaryocytic cell line was obtained from the American
Type Culture Collection (Manassas, VA). The parental and engineered sublines
were cultured in RPMI 1640 with 10% fetal bovine serum (FBS) (Hyclone, Logan,
UT) and 2 mM L-glutamine plus 100 U/ml penicillin and 100 µg/ml streptomycin,
in a 37°C humidified atmosphere containing 5% CO2/95% air. Ara-C, DNR and
VPA were purchased from Sigma-Aldrich (St. Louis, MO).
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2.2.3 shRNA Knockdown of GATA1 in Meg-01 Cells
GATA1 shRNA lentivirus clones were purchased from the RNAi
Consortium of Sigma-Aldrich. Meg-01 cells were transduced with the GATA1
shRNA lentivirus. After selection with puromycin, infected Meg-01 cells were
plated in soft agar. Colonies were isolated, expanded and assessed for GATA1
expression by western blotting and real-time RT-PCR. Two clones with
decreased GATA1 expression (designated GATA1 4-14 and GATA1 5-13) were
chosen for further study. A pool of cells from the negative control transduction
(lentivirus expressing a shRNA with limited homology to any known human
genes) was used as the control (designated GATA1 Neg).
2.2.4 Quantitation of Gene Expression by Real-time RT-PCR
Transcripts were quantitated using primers (Table S1) and Sybr Green
(Roche Diagnostics, Indianapolis, IN) as previously described [53] or Taqman
probes (Applied Biosystems Inc., Foster City, CA) and a LightCycler real-time
PCR machine (Roche Diagnostics, Indianapolis, IN) based on the manufacturer’s
instructions. Real-time PCR experiments were expressed as mean values from
three independent experiments and normalized to GAPDH, with the exception of
GATA1 transcript levels post-VPA treatment, which were normalized to RPL13A
levels as RPL13A has been reported to be a more reliable housekeeping gene
post-HDAC inhibitor treatment [132].
2.2.5 Western Blot Analysis
Whole cell lysates were prepared by sonication in hypotonic buffer (10 mM
Tris-Cl, pH 7.0), containing 1% SDS and proteolytic inhibitors, and subjected to
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SDS-PAGE. Separated proteins were electrophoretically transferred to PVDF
membranes (Thermo Fisher Inc., Rockford, IL) and immunoblotted with
antibodies to GATA1 (C-20, Santa Cruz Biotechnology, Santa Cruz, CA), Bcl-xL
(Cell Signaling Technology, Danvers, MA), or -actin (Sigma-Aldrich, St. Louis,
MO), as described previously [53]. Immunoreactive proteins were visualized
using the Odyssey Infrared Imaging System (Li-Cor, Lincoln, NE), as described
by the manufacturer.
2.2.6 In Vitro Ara-C and DNR Cytotoxicity Assays
For determinations of cytotoxicities, the cell lines were cultured in
complete medium with dialyzed fetal bovine serum in 96-well plates at a density
of 4 x 104 cells/ml for 96 hours. Cells were cultured continuously with a range of
ara-C and DNR concentrations at 37 °C, and viable cells were determined using
the Cell Titer-blue reagent (Promega, Madison, WI) and a fluorescence
microplate reader. The IC50 values were calculated as the concentrations of drug
necessary to inhibit 50% growth compared to control cells cultured in the
absence of drug. The data are presented as the mean values ± standard errors
from at least 3 independent experiments. Standard isobologram analysis was
performed as described previously [225] and combination index (CI) analysis was
performed using CompuSyn software (ComboSyn, Inc., Paramus, NJ)
2.2.7 Assessment of Baseline and Drug Induced Apoptosis
The Meg-01 shRNA stable clones (GATA1 Neg, GATA1 4-14, and GATA1
5-13) in logarithmic growth phase in RPMI 1640/10% dialyzed FBS in the
presence or absence of ara-C and VPA were harvested, vigorously pipetted and
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triplicate samples taken to determine baseline and drug-induced apoptosis using
the Annexin V-FITC Kit (Beckman Coulter; Brea, CA), as previously described
[35,225]. Apoptotic events were recorded as a combination of Annexin V+/PI(early apoptotic) and Annexin V+/PI+ (late apoptotic/dead) events. The data are
presented as mean percentages of Annexin V positive cells ± standard errors
relative to untreated cells.
2.2.8 Chromatin Immunoprecipitation (ChIP) Assay
ChIP assays were performed in Meg-01 cells as previously described [50],
with GATA1 C-terminus (C-20 antibody, Santa Cruz) antibody or normal IgG.
Standard PCR for the Bcl-xL promoter region was performed with forward (5’gcatccccgcagccacctcctc-3’)

and

reverse

(5’-ccctaaaaattccattccccctccag-3’)

primers spanning positions –257 to +67. A separate region (exon 3) of the human
GATA1 gene was also amplified with forward (5’tggagactttgaagacagagcggctgag3’) and reverse (5’-gaagcttgggagaggaataggctgctga-3’) primers to validate the
specificity of the ChIP assays.
2.2.9 ChIP-on-Chip Assay
The ChIP-on-Chip protocol was modified from the Agilent Technologies
Mammalian ChIP-on-Chip Kit protocol at Children’s Hospital of Michigan. Briefly,
genomic DNA from the ChIP assay above was incubated with T4 DNA
polymerase to create blunt ends. Linker DNA was ligated to the blunt end DNA,
followed by amplification of the samples. The samples were labeled, hybridized
to the microarray, washed and scanned according to the manufacturer’s protocol.
Data were imported into Chip Analytics software (v1.3.1, Agilent Technologies)
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for analysis. Normalization was performed using intra-array lowest and interarray median normalizations. Peak detection was performed using the
Whitehead error model (v1.0) and the Peak Shape Detection algorithm (v2.0).
Genes with a bound region (peak) were identified, and the associated NCBI
Refseq accession numbers were used for subsequent analyses. The ChIP-onChIP results were validated by both regular PCR and real-time PCR (see above).
We have deposited the raw data at GEO under accession number GSE43018.
2.2.10 Gene Expression Microarray Analysis
Gene expression microarray was performed with the Agilent Whole
Human Genome 4 x 44K microarray (catalog G4112F) at Children’s Hospital of
Michigan. Microarray sample preparation, hybridization, and data analysis were
described previously [52]. On each microarray, a labeled GATA1 4-14 or GATA1
5-13 sample was co-hybridized with an oppositely labeled GATA Neg sample.
Two arrays were completed for the GATA1 4-14/GATA1 Neg pair and the
GATA1 5-13/GATA1 Neg pair, respectively, for a total of four arrays. The two
microarrays used for each clone were hybridized in a “dye swap” arrangement
with opposite dye orientation to minimize the dye bias effect. Statistical analyses
were performed using Rosetta Resolver® [159]. We have deposited the raw data
at GEO under accession number GSE42879 and we confirm all details are
MIAME compliant.
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2.2.11 Construction of Plasmids, Transient Transfection, and Luciferase
Assay
The GATA1 expression vector, pPacGATA1, and Bcl-x promoter
construct, pGL3B-Bcl-x-pro, were prepared as previously described [49,51]. D.
Mel-2 cells (Invitrogen, Carlsbad, CA) were co-transfected with 1 µg of the Bcl-x
promoter construct and 125 to 500 ng of pPacGATA1 using Fugene 6 reagent
(Roche, Indianapolis, IN), as described previously [49,51]. Luciferase activities
were assayed using the Single Luciferase Assay System (Promega) and
normalized to total cell protein, measured by the Bio-Rad DC-protein assay kit
(Bio-Rad, Hercules, CA).
2.2.12 Production of Lentivirus Particles and Transduction
The pMD-VSV-G and delta 8.2 plasmids were gifts from Dr. Dong at the Tulane
University. The transfection was carried out by using Lipofectamine and Plus
reagents (Life Technologies, Carlsbad, CA) according to the manufacturer’s
instructions. Briefly, RFP (red fluorescent protein) or Bcl-xL cDNA construct from
Thermo Fisher Scientific Biosciences (Lafayette, CO), pMD-VSV-G and delta 8.2
were cotransfected into TLA-HEK293T cells and the culture medium was
harvested 48 h post-transfection. 2x105 cells were transduced overnight by
adding 1 ml of virus supernatant and 4 µg of polybrene (Sigma-Aldrich). Cells
were then triple-washed and allowed to grow for 24-48 hours before addition of
blasticidin for selection. Cells were selected for at least 7 days before being
used for experiments (Invivogen, San Diego, CA).
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2.2.13 Trypan Blue Exclusion Assay
An aliquot of the indicated cells was mixed 1:1 with a 0.4% trypan blue solution
(Sigma-Aldrich, St. Louis, MO) and allowed to incubate for 30 seconds. The
mixture was loaded into a haemocytometer and total cell counts, as well as
trypan blue positive cell counts, were made. Reported results are the percentage
of the total cells that were trypan blue positive and represent the average of at
least three independent counts.
2.2.14 Statistical Analysis
Differences in transcript levels between distinct AML patient groups were
compared using the nonparametric Mann-Whitney two-sample U test. The
nonparametric Spearman rank correlation coefficient was used to analyze the
relationship between GATA1 and Bcl-xL transcript levels. Statistical analyses
were performed with GraphPad Prism 4.0.
2.3 Results
2.3.1 Overexpression of GATA1 in AMKL blasts is associated with
chemotherapy resistance
To determine if GATA1 is overexpressed in AMKL compared to other
subtypes of AML in non-DS children, real-time RT-PCR was performed to
quantify transcript levels of GATA1 in a cohort of diagnostic AML blast samples
(12 AMKL cases and 31 non-AMKL AML cases). GATA1 transcript levels were
significantly higher in AMKL blasts compared to blasts of other AML subtypes
amongst non-DS patients (median 5.5-fold, p=0.004) (Figure 2.1A).
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To explore the role of GATA1 in chemotherapy sensitivity in AMKL,
GATA1 expression was knocked-down using lentivirus shRNA in the non-DS
megakaryocytic cell line Meg-01. Two stable clones, designated GATA1 4-14
and GATA1 5-13, showed decreased GATA1 transcripts [~25% relative to a nontargeted control comprised of a pool of cells infected with a lentivirus negative
control shRNA (designated GATA1 Neg)], while at the protein level, GATA1 was
reduced to approximately one-third and one-half that of GATA1 Neg in the GATA
4-14 and GATA 5-13 clones, respectively (Figures 2.1B&C).

This was

accompanied by significantly increased baseline apoptosis in both clones relative
to the GATA1 Neg cells, as measured by flow cytometry with Annexin V-FITC/PI
staining (Figure 2.1D). Down-regulation of GATA1 also resulted in increased
anti-proliferative activity for ara-C and DNR, as measured by the Cell Titer-Blue
viability assay. The IC50s for ara-C in the GATA1 Neg, GATA1 4-14, and GATA1
5-13 were 48.3 nM, 10.8 nM, and 12.0 nM, respectively, while those for DNR
were 41.6 nM, 27.1 nM, and 18.4 nM, respectively (Figures 2.1E&F).
2.3.2 Bcl-xL is overexpressed in AMKL and is a GATA1 target gene
It was previously reported that GATA1 promotes survival of developing
erythrocytes by upregulating Bcl-xL [58]. On this basis, we hypothesized that
GATA1 could play a potential role in the survival of AMKL blasts upon treatment
with cytotoxic agents by upregulating BcL-xL. To begin to test this possibility, BclxL transcripts were initially measured by real-time RT-PCR in the above cohort of
31 AMKL and 12 non-AMKL AML cases. Consistent with our hypothesis, Bcl-xL
transcript levels were significantly higher (median 4.2-fold; p=0.002) in AMKL
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cases compared to that in other AML subtypes. (Figure 2.3A) The transcript
levels of Bcl-xL closely correlated with GATA1 transcripts in AML and AMKL
blasts (r=0.901, p<0.0001) (Figure 2.3B). Further, in the cell line models,
knockdown of GATA1 resulted in decreased Bcl-xL expression at both the
transcript and protein levels (Figures 2C&D). Bcl-2 protein was not detected by
western blotting in these cells and Mcl-1 levels were comparable to the GATA-1
Neg cells (Figure 2.2A). Finally, the sensitivity induced by GATA1 knockdown
was reduced, at least in part, by exogenous expression of Bcl-xL in the GATA1
4-14 clone (Figures 2.2B&C)
To provide evidence that GATA1 directly activates expression of Bcl-xL by
binding to the putative GATA1 sites in the Bcl-x gene promoter region (Figure
2.3E), ChIP was performed in Meg-01 cells, followed by PCR of the recovered
DNA using primers flanking the putative GATA1 binding sites. As can be seen in
Figure 2.3F, pulldown with the GATA1-specific antibody GATA1 c-20 resulted in
specific precipitation of the Bcl-x promoter region (containing the two putative
GATA1 binding sites) but not an unrelated region. Activation of the Bcl-x
promoter activity by GATA1 was further confirmed using a luciferase reporter
assay after cotransfection of D. Mel-2 cells with increasing amounts of a GATA1
expression vector along with the Bcl-x promoter construct. As shown in Figure
2.3G, increasing amounts of the GATA1 construct resulted in dose-dependent
induction of luciferase expression driven by the Bcl-x promoter. Taken together,
these studies provide direct evidence that GATA1 binds to the GATA1 sites in
the Bcl-x upstream region and transactivates its activity in Meg-01 cells.
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2.3.4 Treatment with VPA down-regulated GATA1 and Bcl-xL and sensitized
Meg-01 cells to ara-C- induced apoptosis
With currently available treatments, it is not feasible to directly target
GATA1 in AMKL cells. Based on a previous report [22], we hypothesized that
treatment with VPA, an HDAC inhibitor, could potentially down-regulate GATA1
expression. Indeed, treatment of Meg-01 cells with clinically achievable
concentrations (0.5 and 1.0 mM) of VPA resulted in a reduction in GATA1 protein
expression, as measured by western blotting (Figure 2.4A), while treatment with
comparably toxic doses of DNR did not (not shown).

Furthermore, VPA

treatment also resulted in decreased expression of Bcl-xL protein (Figure 2.4A).
To investigate the mechanism through which VPA modulates GATA1 expression,
real time RT-PCR was used to look at GATA1 transcript levels post VPA
treatment.

Transcript levels were decreased after both 0.5 and 1.0 mM

treatments, albeit to different degrees (Figure 2.4B).
To determine the impact of VPA treatment on ara-C cytotoxicity, we
measured the viability of Meg-01 cells upon exposure to ara-C, along with
increasing VPA concentrations, using the Cell Titer-Blue viability assay. When
simultaneously administered with ara-C, VPA at 0.5 and 1 mM significantly
enhanced ara-C sensitivity (as reflected in decreased IC50s) by 1.6- and 2.7-fold,
respectively (Figure 2.4C). The combined effects of ara-C with VPA on cell
proliferation were clearly synergistic, as determined by standard isobologram
analysis (Figure 3D) and by calculating CI values. A CI<1 (0.83 and 0.81 for the
combination with 0.5 and 1.0 mM VPA, respectively), indicative of synergism,
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was calculated for each of the drug combinations. In addition, the combination of
VPA and ara-C synergistically induced apoptosis as measured by flow cytometry
with Annexin V-FITC/PI staining (Figure 2.4E). Exogenous expression of Bcl-xL
in Meg-01 cells abrogated the enhancement of ara-C cytotoxicity by VPA and
caused resistance to VPA or ara-C (Figure 2.2B&D)
2.3.5 Identification of additional GATA1 target genes
In order to identify additional GATA1 target genes that may contribute to
chemotherapy resistance, oligonucleotide microarray analyses on RNAs from the
GATA1 5-13/4-14 clones and GATA1 Neg control were performed. Average log
ratios, representing the differences in expression between the GATA1 shRNA
clones and the GATA1 Neg control, were derived for each array feature by
combining replicate array data, using the error-weighted algorithm of Rosetta
Resolver®. Differentially expressed genes were identified by their p-values,
calculated with the Resolver error-model and the replicate data. Using a p-value
≤ 0.005 as cutoff, 3210 differentially expressed features (probes) were identified,
with a false discovery rate of 6.4%. Of these, 1521 were down regulated in the
knockdown clones, while 1689 were upregulated. Validation of the microarray
results was performed using real-time RT-PCR and separate RNA samples from
the Meg-01 stable clones. As shown in Figure 2.5A-B, real-time RT-PCR was
able to validate both up- and down-regulated genes. A full list of differentially
expressed probes can be found in Tables S2 and S3. Interestingly, the downregulated genes were significantly enriched for genes involved in regulating cell
division and cell death, and a large number of the upregulated genes were
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associated with chromatin assembly and organization (Tables S4 and S5,
respectively), as determined by DAVID gene functional annotation analysis
[79,80].
The above oligonucleotide microarray experiment detected both direct and
indirect GATA1 target genes in Meg-01 cells. To identify direct targets of GATA1
among the oligonucleotide microarray gene list, a ChIP-on-Chip experiment was
performed. Validation of the ChIP-on-Chip analyses was performed using both
regular PCR and real-time RT-PCR (Figures 2.5C-D). The gene accession
numbers associated with ChIP-on-Chip peaks (described in methods) were
compared to the accession numbers for the 3210 differentially expressed genes
in the GATA1 knockdown clones. The cross-referencing produced a list of 317
common genes (Figure 2.5E, Table S6) which is likely to be highly enriched for
bona fide GATA1 target genes. Interestingly, there were many genes in this
overlapping group that were found by DAVID ontology analysis to be associated
with either regulation of cell death, cell cycle, or proliferation (Table 2.1.).
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Figure 2.1 GATA1 transcripts are elevated in AMKL blasts and shRNA knockdown
increases basal apoptosis and chemotherapy sensitivity. A: GATA1 transcript levels in
primary non-AMKL AML or AMKL blasts from non-DS patients were quantitated by real-time RTPCR and normalized to GAPDH transcript levels. Median transcript levels were compared
between the two patient groups using the nonparametric Mann-Whitney U test. B-C: Meg-01
cells were infected by GATA1 shRNA lentivirus clones. Colonies were isolated, expanded and
tested for GATA1 expression by real-time RT-PCR (panel B) and Western blotting (panel C).
Two colonies (GATA1 4-14 and GATA1 5-13) with decreased GATA1 gene expression were
selected for further study. A pool of cells from the negative control infection was used as the
control (designated GATA1 eg). D: Baseline apoptosis in the GATA1 4-14, GATA1 5-13 and
GATA1 Neg was determined by flow cytometry with Annexin V-FITC/PI staining. *indicates
p<0.05, error bars indicate standard errors. E-F: Meg-01 GATA1 shRNA clones were cultured in
96-well plates at a density of 4x104 cells/mL in the presence of 0-500 nM Ara-C (panel C) or 0200 nM DNR (panel D) and cell numbers were determined with the Cell Titer-blue reagent and a
fluorescence microplate reader. The data represent mean values ± standard errors from at least
three independent experiments.
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Figure 2.3 Bcl-xL is a bona fide GATA1 target gene in AMKL. A: Bcl-xL transcript levels in
primary non-AMKL AML or AMKL blasts from non-DS patients were quantified by real-time RTPCR. Median transcript levels were compared between the two patient groups with the use of the
nonparametric Mann-Whitney U test. B: The relationship between GATA1 and Bcl-xL transcript
levels was determined by the nonparametric Spearman rank correlation coefficient. C: Transcript
levels for Bcl-xL were quantified by real-time RT-PCR in the Meg-01 shRNA stable clones. Realtime PCR results were expressed as mean values from three independent experiments and
normalized to GAPDH. D: Whole cell extracts from Meg-01 GATA1 Neg., 4-14 and 5-13 were
subjected to Western blotting and probed for Bcl-xL and -actin. E&F: In vivo binding of GATA1
to the putative GATA1 binding sites located in the upstream region of the Bcl-x gene in Meg-01
cells was determined by ChIP assays with the use of regular PCR (panel F), as described in the
“Materials and Methods”. The location of the primers used in 2F are indicated by the arrows in
2E. G: D. Mel-2 cells were transfected with pGL3Basic-Bcl-x-pro along with 0-500 ng of
pPacGATA1 using the Fugene 6 reagent. GATA1 transactivation of Bcl-x promoter was

determined by luciferase reporter gene assays and normalized to total cell protein.
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Figure 2.4 Valproic acid causes down-regulation of GATA1 and enhances ara-C induced
apoptosis in Meg-01 cells. A: Meg-01 cells were treated with VPA for 48h. Whole cell lysates
were extracted, subjected to Western blotting and probed by anti-GATA1, Bcl-xL and -actin. B:
Meg-01 cells were treated at the indicated dose of VPA for 48h and RNA was harvested for
quantification of GATA1 transcripts by qRT-PCR. Transcript levels for GATA1 in the VPA treated
cells were normalized to untreated cells. C: Meg-01 cells were treated with ara-C in the presence
or absence of VPA and viable cell numbers were determined using Cell Titer-blue reagent. IC50
values were calculated as the concentration of drug necessary to inhibit 50% proliferation
compared to control cells cultured in the absence of drug. * indicates p<0.05 D: Standard
isobologram analysis of Meg-01 cell proliferation inhibition by the combined treatment of ara-C
and VPA. The IC50 value for each drug is plotted on the axes; the solid line represents the
additive effect, while the points represent the concentrations of each drug resulting in 50%
inhibition of proliferation. Points falling below the line indicate synergism between drug
combinations whereas those above the line indicate antagonism. The data are presented as
mean values ± standard errors from at least 3 independent experiments. E: Apoptosis after
indicated treatment for 48 hours as determined by flow cytometry with Annexin V-FITC/PI
staining. *indicates p<0.05 relative to no ara-C, error bars indicate standard errors.
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Figure 2.5 Identification of additional GATA1 target genes. A&B: Oligonucleotide microarray
analysis was performed with RNA samples form the Meg-01 shRNA stable clones and the results
were validated by real-time RT-PCR using Taqman probes. GATA1-repressed (panel A) and
GATA1-activated (panel B) transcript levels for MYCN, NCAM1, CD34, ILA1, and EVI1 are
expressed as mean values from three independent experiments and normalized to GAPDH.
C&D: ChIP-on-Chip array analysis was performed in Meg-01 cells and the results were validated
by PCR (panel C) and real-time PCR (panel D) using primers against each region (Table S1). E:
Overlapping genes between oligonucleotide microarray and ChIP-on-Chip array were identified
by cross-reference of the two sets of data using GenBank accession numbers.
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Table 2.1. Overlapping genes associated with cell-cycle, apoptosis, or
proliferation
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2.4 Discussion
Despite progress in the treatment of AML, there are still AML subtypes
such as AMKL that have a poor prognosis. Hence, studies examining the basis
for the relative chemotherapy resistance of these subgroups may lead to
improvements in therapy. The significantly higher cure rates of DS AMKL
patients, who almost uniformly harbor somatic mutations in the GATA1 gene,
suggested that GATA1 may play a critical generalized role in chemotherapy
response and resistance [5,45,106,163,215,236]. This is also supported by
studies which established an association between high expression levels of
GATA1 and a poorer prognosis in adult AML [6,186]. This is particularly relevant
to non-DS AMKL since overexpression of GATA1 in this AML subtype has been
previously observed [171]. However, the molecular mechanisms by which
GATA1 confers chemotherapy resistance in AMKL remain unknown.
This study established that for patients whose leukemic blasts express
high levels of GATA1, one potential mechanism of resistance involves
overexpression of the anti-apoptotic protein Bcl-xL. A direct role for GATA1 in the
expression of Bcl-xL was implicated by knocking down GATA1 in the
megakaryocytic cell line, Meg-01.

Upon knocking down GATA1, Bcl-xL

expression was partially abrogated, accompanied by increased basal apoptosis
and sensitivity to ara-C and DNR.

Although this finding was not entirely

unexpected, as the Bcl-2 family proteins are known to inhibit apoptosis and lead
to chemotherapy resistance, and Bcl-xL has a well-documented role in the
maintenance of the megakaryocyte lineage [98], it nonetheless suggests a
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potential target for patients with AMKL. The Bcl-2 family inhibitor GX15-070 is
currently undergoing clinical trials (www.clinicaltrials.gov) and has shown single
agent efficacy in leukemia patients [143,182].
Another potential approach to enhance the treatment of AML with high
expression of GATA1 involves the use of HDAC inhibitors, combined with
standard chemotherapy regimens. While HDAC inhibitors are well known to
exhibit modest anti-leukemic activities as single agents, preclinical work from our
group has demonstrated their strong enhancement of standard agents [225,226].
In this study, we showed that VPA, an FDA approved anti-epileptic medicine that
also acts as an HDAC inhibitor, was able to down-regulate GATA1 along with
Bcl-xL, resulting in synergistic induction of apoptosis upon addition of ara-C.
Changes in transcript levels post-VPA treatment did not account for the total
differences in GATA1 protein seen in this study (Figure 3A-B), suggesting that
VPA affects both the transcriptional and post-transcriptional regulation of GATA1.
Current clinical trials are investigating the role of HDAC inhibitors as adjuvant
therapies in many cancers, including pediatric AML (www.clinicaltrials.gov).
While Bcl-xL appears to be an important GATA1 target, it was of interest to
identify additional genes that were regulated either directly or indirectly by
GATA1. Using gene expression microarray analysis, we were able to identify
over 3000 genes that were differentially expressed upon GATA1 knockdown
including genes involved in regulating chromatin structure and cell death. By
cross-referencing the differentially expressed genes with regions identified by
ChIP-on-Chip, we were able to generate a list of 317 genes corresponding to
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bona fide GATA1 targets. In addition to these, other potentially important genes
were identified. One such gene is DYRK1A, which encodes the dual-specificity
tyrosine-(Y)-phosphorylation regulated kinase 1A.

This gene was recently

identified as a driver of megakaryocytic leukemia in a mouse DS AMKL model
[127]. Neural Cell Adhesion Molecule (NCAM), which was found to be repressed
by GATA1, is associated with poorer prognosis in AML [162] and early death in
pediatric AML patients [121]. Vascular endothelial growth factor (VEGF) was
identified by the ChIP-on-ChIP to be a direct GATA1 target is indicative of poorer
prognosis [61] and is also a potential therapeutic target in AML [126]. Both Evi1
and CD34 were found to be activated by GATA1 and could potentially contribute
to the poorer outcome found in GATA1 overexpressing patients. Evi1 has been
found to be epigenetically deregulated and associated with poor prognosis in
AML [211]. CD34 is a well-established surface marker present on immature
hematopoietic cells that despite having variable prognostic capacity in mixed
AML backgrounds [93], is of prognostic significance within some subgroups
[151,234]. Though not specifically investigated here, this may suggest a potential
role for the reduction of GATA1 levels in the differentiation induced by HDAC
inhibitors in AML cells [158].
In summary, in this study we were able to further clarify the role of GATA1 in
AMKL. Blasts from patients with AMKL overexpressed GATA1 relative to those
with other AML subtypes. The finding that GATA1 is able to bind and activate
the Bcl-x promoter coupled with the high correlation between GATA1 expression
and Bcl-xL transcript levels in primary patient samples offers a potential
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explanation for why AML patients with high GATA1 expression have been found
to have poorer outcomes. Furthermore, treatment with the HDAC inhibitor, VPA,
was shown to decrease both GATA1 and Bcl-xL expression in Meg-01 cells and
sensitize them to treatment with ara-C. Finally, by combining gene expression
microarray and ChIP-on-Chip analyses, we were able to identify additional
GATA1 target genes to serve as a basis for future studies of both potential
chemotherapeutic interventions and AMKL biology
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CHAPTER 3 – Identifying New Therapeutic Options for the Treatment of
Down Syndrome Acute Myeloid Leukemia
3.0 Preface
As discussed in Chapter 1 of this work, there remains a subset of DS-AML
patients that, despite best clinical efforts, continues to have poor outcomes. This
chapter will cover the important background information and preliminary work
that culminated in the selection of the wee1 inhibitor MK-1775 for further study,
the results of which are presented in Chapter 4 of this work.
3.1 Standard Chemotherapeutic Agents for the Treatment of DS-AML
In order to effectively design new therapies for the treatment of any
disease, it is first important to understand the mechanisms by which current
therapies work (or do not work). By considering these mechanisms, it is possible
to focus research efforts on rationally targeted therapies. The two compounds
that have formed the backbone of pediatric AML treatment regimens for decades
are araC and DNR.

Figure 3.1 Chemical structures of araC and DNR
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3.1.1 araC
One of the older anticancer drugs, araC was originally modeled after a
compound first isolated from a marine sponge. After observing the effects of the
original “spongothymidine”[11], a cytidine analogue with an arabinose replacing
the ribose was synthesized and found to have anti-cancer properties[36].
3.1.1.1 Incorporation of araC

There are many potential intracellular

targets for nucleoside analogues, including interruption of signaling cascades,
metabolic processes, and DNA synthesis and maintenance, with araC targeting
the last of these. Itself a pro-drug, araC undergoes stepwise phosphorylation
inside the cell to become araCTP (see below) and becomes an eligible substrate
for DNA polymerases. Despite being initially recognized by the polymerase, as a
result of its arabinose sugar moiety, araC is a poor substrate for further
elongation.

Though there have been somewhat contradictory findings with

regards to the robustness of chain termination after araC incorporation and the
relative importance of different polymerases, many of these studies were
performed using either cell-free systems or low-processivity polymerases,
making the importance of these findings difficult to interpret.

However, it is

generally agreed upon that araC incorporation levels correlate with and are
necessary for its toxic effects.[20,46,62,64,88,102,103,144,150,154,167,220]
3.1.1.2 Intracellular metabolism of araC As a nucleoside, the fate of araC
is regulated by the same enzymes responsible for normal nucleoside
metabolism. Predictably, variations in the expression levels of these enzymes
are some of the best-understood mechanisms of resistance to araC[43,105,129].
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The main protein believed to be important for araC transport into the cell is the
human equlibrative nucleoside transporter 1 (hENT1) encoded by the SLC28A1
gene. As its name suggests, hENT1 is equilibrative as opposed to concentrative,
meaning that araC primarily crosses the plasma membrane by a process of
facilitated diffusion. Decreased expression of hENT1 has been associated with
resistance to a variety of nucleoside analogues, including araC, in both AML and
ALL patients [48,83,192].

Fortunately, there are data to suggest that during

courses of high-dose araC plasma concentrations reach levels such that araC
transport is saturated and is no longer limited by hENT1[152,218].
Before intracellular araC can be incorporated into DNA, it must first be
phosphorylated three times to araC-triphosphate (araCTP). The first of these
phosphorylation events is the rate-limiting step, and is catalyzed by the enzyme
deoxycytidine kinase (dCK). It has been shown that reductions in dCK activity
are not only associated with acquired resistance or relapse[12,92], but that
exogenously

induced

expression

can

rescue

sensitivity

to

nucleoside

analoges[63]. After the initial phosphorylation event, araC is subsequently diand tri-phosphorylated similar to physiologic nucleosides by enzymes that have
not been associated with chemotherapy sensitivity.
Also important for the intracellular levels of araC is the enzyme cytidine
deaminase (CDA). Normally involved in pyrimidine salvage, CDA can deaminate
araC or its phosphorylated derivatives into uracil arabinoside, or araU. As uracil
is not a candidate for incorporation into DNA, araU is inactive. Accordingly, high
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levels of CDA are associated with nucleoside resistance, while low levels have
been associated with more favorable outcomes [90,184].
3.1.2 DNR and other Topoisomerase II Poisons
The mechanism of action of drugs in this class has been surprisingly
controversial, despite almost constant study since the first isolation of DNR in
France in 1963 [123]. The biology and relevance to cancer chemotherapy of this
class of compounds has been reviewed excellently in [55,137,138], from which
much of this overview has been drawn.
Daunorubicin belongs first to a class of drugs known as the
anthracyclines, and then to a larger class known as topoisomerase II (Topo2)
poisons. The anthracyclines are all derived from Streptomyces species bacteria
and share similar chemical structure to each other, as well as the prominent
anthracycline analogue mitoxantrone. The other predominant drug in the Topo2
poison class is etoposide (VP16), which belongs to the class of drugs known as
epipodophyllotoxins.
Type-two topoisomerases are responsible for the decatenation of DNA
after replication. Unlike type-1 enzymes which cause single strand breaks and
allow for relaxation of supercoils, type-2 enzymes introduce double strand breaks
(DSB) in one chain, allowing a second to pass through the gap, followed by
ligation of the break.

The reason that agents of this class are referred to as

poisons is that the presence of their target enzyme, either topoisomerase II α or
β, are required for them to exert their toxic effect. In fact, expression levels of
Topo2α have been shown to be major determinants of chemotherapy response
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[17]. While the exact details are unclear, it is known that Topo2 poisons bind to
Topo2 and prevent its decatenation activity. The preponderance of evidence
suggests that these drugs do this by locking the enzyme in what is referred to as
a “covalent complex” between it and the newly cleaved DNA. The result is not
only a DNA DSB, but also a covalently linked DNA-enzyme complex that is
difficult to remove.
3.1.3 Cellular effects of araC and DNR treatment
As with most chemotherapeutic treatments, the goal of treating with both
araC and DNR is to kill the cancer cell, typically through apoptosis. The exact
cellular processes that exert these effects are vast, and in many cases are still
being elucidated. In general, however, it is believed that these agents induce
apoptosis primarily by elucidating a DNA-damage response. Though a thorough
review of these processes is beyond the scope of this work, (excellent coverage
of the topic may be found in [7,135,178]), the general trend is that araC induces
S-phase DNA damage[37] and DNR induces G2- and M-phase DNA
damage[138]. The first response to DNA damage is typically cell-cycle arrest,
giving the cell time to repair the damage prior to division or DNA replication.
However, if the damage is sufficiently severe, the cell undergoes apoptosis.
Alternatively, damage can go unrepaired with two potential outcomes. The first is
the introduction of de novo mutations or chromosomal abnormalities, and the
second is mitotic catastrophe.
chromosome-level

damage

Mitotic catastrophe occurs when cells with

undergo

mitosis,

resulting

in

non-standard

segregation of genetic material. This is typically incompatible with further growth
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and results in cell death. However, in either case, if the cell does not die, the
altered genetic material is then passed along to the next generation.
3.1.4 Toxicities of araC and DNR
3.1.3.1 Toxicity of therapy with araC Despite being the primary backbone
of most therapeutic regimens, araC treatment is associated with profound
toxicity.

Most patients suffer substantial myelosuppression, resulting in

neutropenia, thrombocytopenia, and anemia.

While thrombocytopenia and

anemia are treatable with transfusion if necessary, neutropenia is not.
Neutropenic patients are at a substantially elevated risk for infection, and
prophylactic antibiotics directed against both bacteria and fungi are now being
used more commonly as supportive care in leukemia protocols. Other adverse
effects include corneal toxicity, which can be managed prophylactically with
steroid eye-drops, and common chemotherapy side effects like alopecia, nausea,
and gastrointestinal toxicity. [75,173]
3.1.3.2 Toxicity of therapy specific to DNR

When considering

chemotherapy with Topo2 poisons, there are two specific late effects that are of
special note. The first is an elevated risk of secondary malignancy, specifically
tAML.

Though secondary malignancy is a risk of any DNA damaging

chemotherapeutic agent, Topo2 poisons (especially VP16) have been associated
with a greatly enhanced risk of tAML[39,148]. The second is the well-established
risk for cardiotoxicity (e.g. decreased left ventricular function) after treatment with
anthracyclines. Cardiotoxicity can manifest either early (within one year) [100] or
late [84,228], and though not all cardiotoxicity in cancer survivors is related to
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anthracyclines [113], it is still concerning such that anthracycline administration is
typically limited by lifetime cumulative doses.
While the effects of Topo2 poisons on secondary malignancy incidence
are considered undesirable on-target effects, there is much debate as to the
underlying mechanism behind the cardiotoxic effects of anthracyclines. Early
work in this field showed that anthracyclines were able to redox cycle due to their
quinone moiety, and that this effect was especially prominent in the presence of
iron. These findings lead to the belief that anthracyclines exerted their toxic
effects through reactive oxygen species- (ROS) mediated damage.

A

consequence of this belief was that investigators designed iron-chelators to help
protect cardiac tissue from ROS generation, one of which was dexrazoxane.
Interestingly, dexrazoxane has been shown to also catalytically inhibit Topo2,
which could theoretically block the activity of Topo2 poisons [55,137,138]. The
debate regarding the mechanism of cardiac toxicity still continues, with recent
studies pointing at on-target effects of anthracyclines and their action on Topo2β
as well as mitochondrial iron accumulation in cardiac tissue [86,231].
Furthermore, while recent clinical studies have shown benefit of dexrazoxane
adjuvant therapy [114], other studies have associated its use with an increased
incidence of tAML[176,205], and the FDA has since changed its approval to only
apply to adult breast cancer patients who have received high doses of
anthracycline (www.FDA.gov).
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3.2 Chemotherapy sensitivity in DS patients
As mentioned in Chapter 1 of this work, DS-AML patients have a unique
response to chemotherapy compared to non-DS patients. Most importantly, it
has been shown that leukemic blasts from DS patients are more sensitive to
chemotherapy. Two studies from this group demonstrated that DS-AML blasts
generate higher levels of the active araC metabolite araCTP[202,203].

This

was at least partially due to increased expression levels of cystathionine-βsynthase (CBS), which is located on chromosome 21.

Increased CBS

expression impacts the folate cycling pathways involved in nucleoside pool
maintenance thereby decreasing the intracellular pools of dCTP.

As dCTP

inhibits the araC-activating enzyme dCK, elevated CBS levels have been shown
to correlate with araCTP levels and increase survival in an in vivo mouse
xenograft leukemia model[201,202]. A 1999 study replicated these findings,
showing that DS-AML blasts were more sensitive to both araC and doxorubicin
(an anthracycline like DNR), but that this trend did not hold true for DS-ALL
blasts[42]. Another mechanism contributing to this sensitivity is the impact of
GATA1 mutations in DS-AML on CDA expression. Two studies from this group
demonstrated that CDA is a GATA1-target gene, and that GATA1s mutants are
less-capable of activating CDA expression, resulting in higher araCTP levels and
higher sensitivity to araC[51,53]. Further, more recent work from this group has
demonstrated that DS-AML has a unique gene expression profile compared to
non-DS-AML, and that GATA1s also has positive functions promoting the growth
and survival of DS-AML blasts[49,222].
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The

increased

sensitivity

of

DS-AML

blasts

to

chemotherapy,

unfortunately, also extends to DS-AML patients, who are at a greater risk for
treatment related toxicity. In addition to being more susceptible to infection at
baseline as a result of having DS, DS-AML patients have historically suffered
from increased treatment-related mortality secondary to infectious complications,
although more recent protocols have seen greater success at avoiding these
unfavorable outcomes[44,106,161]. Of special concern is anthracycline use in
this population. At least partially as a result of the high incidence of congenital
heart defects in this population, DS patients are more likely to develop
cardiotoxicity, and it that toxicity which may be lethal[100,142].
3.3 Identifying new therapies for DS-AML – approach
In order to further improve outcomes for DS-AML patients, new
therapeutic approaches must be developed. As mentioned in Chapter 1, there
are subsets of DS-AML patients who have poor outcomes, and transplant is not
an attractive option in the DS-AML population. Furthermore, toxicity continues to
be a concern for these patients. With the goal of this study being to identify new
chemotherapeutic options, a careful approach to maximize the clinical potential
of our findings was important.
The first important consideration is that any results obtained should be as
rapidly translatable to the clinic as possible. Though there are exciting options
emerging from early-stage investigational drugs, agents that are not already
under clinical study are less likely to be tested in the DS population even in the
distant future.

Therefore, we set out to provide a foundation supporting the
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immediate inclusion of new agents into DS-AML treatment protocols upon the
approval of drugs currently under investigation for other patient groups.
Moreover, this limits the investigation to agents that show effects within clinically
achievable concentration ranges. Finally, as a result of responsible clinical study
design, any agents selected for study must show at least additive effects with
araC, as it is unlikely that study arms would withhold this standard of care agent.
The rest of the considerations driving agent selection are of a more
practical nature. Though there has been much recent progress in the field of
oncology with regards to biologic therapies (e.g. antibodies and other
immunotherapies) these treatments are difficult to interrogate in vitro using our
model system (see below).

Also important was that any compound tested

needed to be available. Finally, agents were chosen in a way that was perceived
to minimize the replication of effort such that either knowledge or perception of
extensive study by either collaborators or outside groups precluded inclusion in
this study.
3.4 Cell line models
In order to begin investigations into new therapeutic options for DS-AML,
model systems needed to be utilized as primary research in patients is neither
feasible nor ethical. The model systems used herein are two DS-AML cell lines,
derived from DS children with AMKL. The first, CMK, was derived from a patient
who presented first with sensitive disease but unfortunately suffered a relapse
[181]. The second, CMY was derived from a patient who suffered from primary
refractory disease [131]. Though both of these cell lines harbor p53 defects that
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were not present in the primary disease, they are both of the AMKL phenotype
with confirmed GATA1 mutations, and are thus reputable cell line models.
3.4.1 Initial characterization of DS-AML cell lines
The first step in characterizing the CMK and CMY cell line models was
determining their response to the standard chemotherapeutic agents, araC and
DNR.

Utilizing a 3-day 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium

bromide (MTT) assay (methods described in Chapter 4), it was found that CMY
was significantly more resistant to both agents than was CMK (Figure 3.2A).
Because both araC and DNR are cell-cycle phase dependent (S- and G2/M,
respectively), the proliferation rate of the two cell lines was determined by serial
cell counts for 3 days. It was found that CMY does in fact proliferate more slowly
than CMK (doubling time 33 vs 22 hours) (Figure 3.2B). Next, the expression
levels of proteins associated with araC and DNR sensitivity (hENT1, dCK,
Topo2α), as well as Bcl-2 family proteins associated with resistance to apoptosis
(reviewed in [33]), were interrogated via western blot. Because expression of
Bcl-2 family proteins are thought to be able to compensate for one another, it
was found that the only substantial difference was in the expression of Topo2α,
which was lower in CMY (Figure 3.2C). Finally, it was of interest to determine
the response of CMK and CMY cells to treatment with additional agents already
under investigation to determine if the relative resistance to araC and DNR was
due to CMY cells being globally more resistant or if the resistance was specific to
those two classes of agents (Figure 3.2D). Again using a 3-day MTT assay, it
was shown that CMY displayed class-wide resistance to the nucleoside

71

analogues araC, clofarabine, and decitabine, as well as to the Topo2 poisons
DNR, etoposide, and mitoxantrone.

This class-wide resistance to the Topo2

poisons was not unexpected, as CMY cells possess lower levels of the target
protein Topo2α (Figure 3.2C). Interestingly, no cross-resistance was observed
for the HDAC inhibitors vorinostat (also known as suberanilohydroxamic acid,
SAHA), panobinostat (also known as LBH-589) and mocetinostat (also known as
MGCD0103).

Similarly, there was no difference in sensitivity to the multiple

kinase inhibitor sorafenib. Interestingly, CMY was actually more sensitive to the
proteasome inhibitor bortezomib (also known as velcade) than CMK, although it
is difficult to make a claim for biological significance with only a 2 nM difference
in IC50s. Based on these results, it was determined that CMY is not globally
resistant to all treatments compared to CMK, and that it would be possible to find
an agent that may be similarly effective in resistant and sensitive cases.
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Figure 3.2 Initial characterization of the CMK and CMY cell lines. A: CMY cells are more
resistant to both araC and DNR than CMK cells as measured by 72 hour MTT assay. B: CMK
and CMY cells were plated at similar densities and counted every day while the cells remained in
logarithmic phase growth. Error bars represent standard error on the mean values from three
independent experiments. C: Expression levels of the indicated proteins were interrogated using
western blots on lysates from untreated, logarithmically growing cells. Representative images are
shown. D: The sensitivities to the indicated agents of both CMK and CMY cells as measured by
72 hour MTT assays.
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3.4 Identifying new agents
From the results shown in Figure 3.2, it was determined that it is unlikely that
either nucleoside analogues or topoisomerase poisons would likely produce
favorable results. Because araC requires cells to be in S-phase for it to exert its
toxic effects, agents that have shown promise in other studies but cause
proliferative arrest, like cyclin dependent kinase (CDK) inhibitors and rapalogues,
were not eligible for consideration in this study. It was hypothesized that agents
that either targeted cells post-S phase or cell cycle checkpoints could be very
promising, especially given the pre-clinical successes of Chk1 inhibitors[19,34].
The four targets chosen for further study were the aurora kinases A and B, pololike kinase (Plk)1, and the wee1 kinase. The first three of these will be covered
in this chapter, while the results concerning wee1 can be found in Chapter 4 of
this work.
3.4.1 Aurora kinases A and B and Plk1
In recent years, the aurora kinases and Plk1 have been the subject of
great clinical interest for the treatment of malignancy. Studies have shown that
the aurora A and B kinases as well as Plk1 are overexpressed in AML cells,
compared to normal bone marrow cells[65,81,87,165]. Furthermore, preclinical
work demonstrated a favorable effect of inhibitors of these kinases on AML cell
lines

and

primary

AML

blasts,

experiments[57,65,81,87,97,165,227].

in

in

vivo,

ex

vivo,

and

in

vitro

Thus, it is important to understand the

mechanism of action of these kinases, as well as the effect their inhibition has on
proliferation.
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3.4.1.1 Functions of the Aurora A and B kinases and Plk1 The general
role played by these kinases is the regulation of the transition between the G2
phase of the cell cycle and subsequent mitotic processes (For excellent reviews
on the functions of these proteins, see the reviews by Lens et al., Stebhardt,
Goldenssn and Crispino, and Farag [38,56,109,197]). After a cell has finished
replicating its DNA, preparations are made to allow for successful completion of
mitosis. The processes underlying mitosis are extremely complicated, but there
are some major milestones that must be met in order to ensure that proper
segregation of genetic material and formation of the proper number of daughter
cells occurs. For the purposes of this discussion, emphasis will be placed on the
successful alignment of chromosomes at the metaphase plate and the formation
of a bipolar spindle assembly.
Under normal conditions, after replication, cells are free to enter into
mitosis even in the absence of aurora A kinase and Plk1.

However, in the

presence of G2 checkpoint activation, these proteins become necessary for
further cell cycle progression [116,125,209]. Normally, CDK1 activity is high after
S-phase, and in combination with its partner cyclin B, it phosphorylates a host of
targets required for mitotic entry.

However, in the presence of checkpoint

activation, the inhibitory phosphorylation on CDK1 provided by the wee1 kinase
is not effectively removed, preventing mitotic entry. To progress, aurora A kinase
activates Plk1, which subsequently phosphorylates wee1, leading to its
degradation[213] and allows for an increase in CDK1 activity. This starts a feedforward loop in which CDK1 further activates aurora A kinase and Plk1, allowing
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for mitotic entry. In contrast, aurora B kinase is not required for mitotic entry,
although, interestingly, inhibition during interphase is capable of disrupting
normal mitotic chromosomal organization[68].

After mitotic entry, aurora A

kinase and Plk1 cooperate to form a bipolar spindle assembly while aurora B
kinase

and

Plk1

cooperate

to

regulate

chromatid

cohesion

and

chromosome/microtubule interactions. Following initiation of anaphase, all three
proteins begin degradation and mitosis completes[109].
Inhibition or down-regulation of these kinases causes interesting, albeit
complicated effects.

Aurora A kinase inhibition rapidly leads to aneuploidy

secondary to ineffective spindle formation and chromosome segregation
[74,128]. Aurora B kinase inhibition, on the other hand, leads to bypass of mitotic
arrest and tetraploidy, with the potential for further genetic replication, although
apoptosis is the likely outcome[91]. Contrary to both of these, is the result of
Plk1 inhibition, which leads to robust arrest in early mitosis and subsequent
mitotic death[193].
3.4.1.2 Introduction to inhibitors used in this study When studying the
effects of inhibiting kinases, results are only as reliable as inhibitors are specific.
Fortunately, specific inhibitors for all three of these kinases have not only been
developed, but are in early-stage clinical trials, so some pharmacokinetic data
are available. To inhibit Plk1, the compound BI6727 was used. This agent has
been shown to be safe in phase 1 and 2 clinical trials, with maximal plasma
concentrations exceeding 1 μM, although in the more recent study the Cmax was
only approximately 400 nM[183,191]. It is worth noting, however, that at the
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conclusion of the Phase 2 trial, it was determined that BI6727 did not have
sufficient single-agent activity against urothelial cell carcinomas to be further
pursued as a single agent[191].
Barasertib, also known as AZD1152, is a selective aurora B kinase
inhibitor. A pro-drug, AZD1152 is converted in vivo to the active form AZD1152HQPA, which has been shown to be safe and possibly effective for elderly
patients with advanced AML[94,95,122].

The half-life of this compound is

prolonged, at approximately 77 hours, but its maximum plasma concentration is
relatively low, approximately 400-500 nM when used alone[94,122], and only
approximately 300 nM in the presence of low-dose araC[95].
Finally, alisertib, or MLN8237, is an orally-dosed selective inhibitor of
aurora A kinase. Early results have been published for studies investigating the
use of this agent in both lymphomas and advanced solid tumors[21,41]. In both
studies, MLN8237 was tolerated, showed promising efficacy, and had maximal
plasma concentrations between 1 and 2 μM, with a half-life on the order of 15
hours[21,41]. Importantly, MLN8237 was identified in pre-clinical studies by John
Crispino’s group to be especially promising for the treatment of DS-AMKL, as it
was shown to induce polyploidization and differentiation of CMK cells as well as
non-DS AMKL blasts[217].
3.5 Effect of aurora kinase and Plk1 inhibition on araC sensitivity in CMK
and CMY
In order to begin investigations of the effects of aurora and polo-like
kinase inhibition on the araC sensitivities of CMK and CMY cells, standard 3 day
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MTT was performed to determine the appropriate concentration ranges for these
agents for combination study. Concentration ranges were initially chosen based
on preliminary results from clinical trials, with the goal that concentrations that
were not clinically relevant would not be pursued. The only agent for which this
was problematic was AZD1152-HQPA, as CMY cells were relatively insensitive
to this drug at clinically achievable concentrations (see Figure 3.4). However,
only minor increases over what is clinically relevant (1,000 nM) were required to
generate appropriate response curves.
After identification of the proper concentration range, the effect of the
combination of araC and the inhibitor of interest was determined again using 3day MTT. The effects of the single drugs on CMK and CMY cells could be
compared readily by their respective IC50s, but comparison of their interactions
with araC required further analysis.
In order to compare the combined effects, standard isobolograms and
combination indices (CIs) were used.

Isobolograms represent a simple

visualization that takes into account the desired parameter (in this case IC50) for
each drug and allows for quick assessment of the nature of the effect of the drug
combination. Each axis represents the concentration of the indicated drug. Any
combination that lies below the line connecting the points representing the IC50 of
both drugs is considered to be “synergistic”, those on the line are considered
“additive”, and those above the line are considered “antagonistic”. It is important
to recognize that for a given isobologram, a desired effect level must be predetermined. For these cases, an effect of 50% viability compared to untreated
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cells was used. The same range of araC was tested in the presence of no
additional drug, and three increasing concentrations of the second drug, so each
plot has 5 total points: each drug alone, and the three points representing the
araC concentration required to inhibit 50% of cell growth in the presence of the
given secondary drug concentration.

For the isobolograms presented in this

section, the axes were normalized to the IC50 for each drug such that it was equal
to 1. The benefit of this approach is two-fold: it allows for better visualization of
reproducibility, since each combination point gets both X and Y error bars, and it
makes visual comparison between the two cell lines more direct. Alternatively,
synergy can be calculated using the median-effect principle from Chou and
Talalay.

In this system, a CI < 1 indicates “synergy”, CI > 1 indicates

“antagonism”, and a CI of 1 indicates “additivity”. For a comprehensive review of
the principles of designating synergy in drug combination studies, see Chou’s
2006 review [27]. CIs were determined using the CompuSyn software.
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Figure 3.3 CIs for the combination with araC. The CIs representing each point on the
isobolograms in Figures 3.4-3.6 are plotted, with each point here representing an individual trial.
The CIs were compared to a theoretical median of 1.0 (indicating additivity) using the Wilcoxon
Signed Rank Test; p-values and results can be found in the text.
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Figure 3.4 The combination of AZD1152-HQPA and araC in CMK and CMY cells. A: The
chemical structure of AZD1152-HQPA. B: The effect of AZD1152-HQPA on the percent of
viable CMK and CMY cells as measured by 3-day MTT assay. Data points represent average
values from 3 independent experiments while error bars represent standard error of the mean. C
and D: Normalized standard isobologram analysis of the interactions between araC and
AZD1152-HQPA on cell viability. Each axis represents the concentration relative to the IC50 of
that drug, which was normalized to 1.0. Each point represents the average value from 3
independent experiments, with error bars representing standard error of the mean. X-error bars
represent mostly variation in the IC50 of AZD1152-HQPA, while Y-error bars represent variation in
both the combined effect of both drugs as well as the variation in the IC50 of araC.
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Figure 3.5 The combination of MLN8237 and araC in CMK and CMY cells. A: The chemical
structure of MLN8237. B: The effect of MLN8237 on the percent of viable CMK and CMY cells
as measured by 3-day MTT assay. Data points represent average values from 3 independent
experiments while error bars represent standard error of the mean. C and D: Normalized
standard isobologram analysis of the interactions between araC and MLN8237 on cell viability.
Each axis represents the concentration relative to the IC50 of that drug, which was normalized to
1.0. Each point represents the average value from 3 independent experiments, with error bars
representing standard error of the mean. X-error bars represent mostly variation in the IC50 of
MLN8237, while Y-error bars represent variation in both the combined effect of both drugs as well
as the variation in the IC50 of araC.
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Figure 3.6 The combination of BI6727 and araC in CMK and CMY cells. A: The chemical
structure of BI6727. B: The effect of BI6727 on the percent of viable CMK and CMY cells as
measured by 3-day MTT assay. Data points represent average values from 3 independent
experiments while error bars represent standard error of the mean. C and D: Normalized
standard isobologram analysis of the interactions between araC and BI6727on cell viability. Each
axis represents the concentration relative to the IC50 of that drug, which was normalized to 1.0.
Each point represents the average value from 3 independent experiments, with error bars
representing standard error of the mean. X-error bars represent mostly variation in the IC50 of
BI6727, while Y-error bars represent variation in both the combined effect of both drugs as well
as the variation in the IC50 of araC.
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3.5.1 The combination of AZD1152-HQPA and araC in CMK and CMY cells
As seen in Figure 3.4B, CMK and CMY cells displayed different sensitivity
to the aurora B kinase inhibitor AZD1152-HQPA, with IC50s of 183 nM (95% 151216nM) and 689 nM (95% 652-725 nM), respectively. Respecting the maximally
achievable plasma concentration of 300-400 nM, combination doses tested were
lower relative to the IC50 of CMY than CMK due to the relative insensitivity of
CMY cells to AZD1152-HQPA (Figure 3.3C-D). It can be seen that the effect of
the combination of araC and AZD1152-HQPA trended towards additivity with
CMK demonstrating slight antagonism and CMY showing slight synergism. This
relationship was similarly seen when CI was used as the metric (Figure 3.3). For
both cell lines, their CIs (median 1.1 and 0.87 for CMK and CMY, respectively)
were found to be significantly different than a theoretical median of 1.0 by the
Wilcoxon Signed Rank test (p=0.02 for both cell lines).
3.5.2 The combination of MLN8237 and araC in CMK and CMY cells
As seen in Figure 3.5B, CMK and CMY displayed different sensitivities to
the aurora A kinase inhibitor MLN8237, with IC50s of 19 nM (95% 16-23nM) and
40 nM (95% 29-53 nM), respectively. Though this difference is relatively large
(approximately 2-fold), it is possibly insignificant given the achievable plasma
concentrations exceeding 1 μM [21,41]. In contrast to the response seen for the
combination of araC and AZD1152-HQPA, both CMK and CMY demonstrated an
additive-to-antagonistic response to this combination (Figure 3.5C and D).
When using CI to determine the nature of the interaction between MLN8237 and
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araC (Figure 3.3), only those for CMY (median 1.3, vs 1.1 for CMK) were found
to be significantly different than a theoretical median of 1.0 (p=0.01 and 0.16 for
CMY and CMK, respectively).
3.5.3 The combination of BI6727 and araC in CMK and CMY cells
As seen in Figure 3.6B, CMK and CMY were differentially sensitive to
BI6727, although interestingly, CMK was the more resistant cell line in this case.
CMK and CMY had IC50s of 50 nM (95% 38-62nM) and 30 nM (95% 23-36 nM),
respectively. Similar to both AZD1152-HQPA and MLN8237, the isobologram
analyses (Figure 3.6C and D) did not appear to display any synergism between
araC and BI6727, instead trending towards antagonism. In fact, the CIs for these
interactions were both found to significantly differ from a theoretical median of 1.0
(CI 1.1, p=0.02 and CI 1.2, p=.008 for CMK and CMY, respectively).
3.6 Discussion
Unfortunately,

despite

promising

preclinical

[14,21,41,74,81,87,91,94,95,122,128,183,191,193,217],

and

clinical

findings

AZD1152-HQPA,

MLN8237, and BI6727 all lacked promise in these preliminary studies. While all
three agents demonstrated single-agent efficacy at clinically achievable
concentrations in the CMK cell line, only MLN8237 and BI6727 were effective in
CMY cells. Furthermore, the combination of these agents with araC resulted in
additive-to-antagonistic interactions in each case.
Although these agents were not chosen for further investigation in this
study, it is not to say that there is no potential place for them in the clinical setting
for the treatment of DS-AML. It is certainly possible that the design of this study
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was not optimal to demonstrate a favorable effect of these agents. One potential
cause may have been the selection of the 3-day time point. It may be the case
that had these experiments been terminated at 48 or 96 hours, different results
would have been found, however, the 72 hour time point yielded reproducible
results for araC treatment and was thus used here. It is also possible that had a
different effect level been interrogated (e.g. IC75 or IC90), a different trend may
have emerged.

While the utility of higher effect levels in investigating

chemotherapy drug effects can definitely be argued, it is the opinion of this
author that when using in vitro cell line models, IC50 is more typically
communicated in the literature and is therefore a better endpoint for these
preliminary-type studies.

Further, the experiments presented above were

designed around finding a 50% effect size; therefore the concentration ranges
tested did not produce results suitable for analysis at higher effect levels,
prohibiting robust post-hoc analyses. It is worth noting that, in the context of in
vivo models, the utility of higher effect levels is much greater, as typically the goal
of treatment is disease eradication, not simply a 50% reduction in tumor burden.
In contrast to these agents, which did meet not the relatively strict criteria
for further study, a first-in-class inhibitor of the wee1 kinase, MK-1775, did in fact
demonstrate favorable effect. The results of the preliminary studies with MK1775, as well as a further characterization of the mechanism of its effect in DSAML cells are found in the next chapter of this work.
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CHAPTER 4 - Targeting the wee1 Kinase for Treatment of Pediatric Down
Syndrome Acute Myeloid Leukemia
4.0 Preface
This chapter is taken in its entirety from a manuscript recently accepted by
the journal Pediatric Blood & Cancer.

Though the text will likely be almost

identical to the final published copy, figure numbering has been adjusted to
conform to dissertation standards. What was originally an online supplement has
been incorporated into this work. This author was responsible for the design and
execution of all experiments described herein, with the exception of the ex vivo
experiment presented in Figures 4.3F (designed by this author, performed by
Holly Pitman) and the flow cytometry experiments, which were designed, set up,
and analyzed by this author but the steps involving the cytometer were
performed by Steve Buck.
4.1 Introduction
Pediatric acute myeloid leukemia (AML) remains a difficult disease to treat and is
associated with a relatively guarded prognosis. Patients with Down syndrome
(DS), however, typically have much better outcomes, despite having an
increased risk of developing AML[223]. This is due to enhanced sensitivity to
cytarabine (araC) and daunorubicin imparted by the unique biology of AML in the
DS population (DS-AML), in which most cases are the megakaryocytic (AMKL)
subtype and have somatic mutations in the X-linked transcription factor GATA1
gene[51,53,201,203,215].
Despite favorable outcomes, there are still challenges in treating this
group of children. Patients with DS-AML who experience either an induction
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failure or relapse have dismal prognoses and very few options for
salvage[119,120,199]. DS patients with relapsed AML treated on the Pediatric
Oncology Group (POG) 9421 and Children’s Cancer Group (CCG)-2891 AML
studies had an overall survival (OS) rate of 12%, while a Japanese study
reported an OS of 25.9% for relapsed and refractory DS AML patients[118,200].
DS-AML patients experience greater adverse toxicity, preventing the use of
higher chemotherapy doses, and the high prevalence of congenital heart defects
in

the

DS

population

makes

anthracycline

use

especially

challenging[100,107,141,161]. Following stem cell transplants (SCT), DS-AML
patients only had an OS of 19% [72]. These studies all highlight that DS patients
with refractory/relapsed AML have extremely chemotherapy-resistant disease.
Thus, there is a clinical need for more effective therapies to be developed to treat
this subgroup of DS-AML patients.
Inhibition of the wee1 kinase has recently been identified as a potential
option for the treatment of several malignancies. The wee1 kinase is responsible
for

adding

inhibitory

phosphorylation

to

the

tyrosine-15

residue

of

CDK1[146,214]. This phosphorylation is required for the activation of S-phase
and G2/M cell cycle checkpoints through the CHK1 pathway which inhibits cdc25
phosphatases, which under normal circumstances constitutively remove the
inhibitory phosphates, keeping CDKs active[115,149,179,232].

Therefore,

preventing this initial phosphorylation event should abrogate these checkpoints
that are induced by genotoxic chemotherapy drugs. Indeed, early studies have
demonstrated a benefit of combining the first-in-class wee1 inhibitor, MK-1775
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(currently in Phase 1 and 2 clinical trials), with standard chemotherapy drugs in a
variety of malignancies, including AML[15,23,60,69,70,99,160,208].
In this study, we investigated the potential role for the addition of MK-1775
to araC for the treatment of DS-AML. Using the clinically relevant DS AMKL cell
lines, CMK and CMY, and ex vivo primary DS-AML blast samples, we
determined that MK-1775 was able to synergistically enhance the cytotoxicity of
araC. Furthermore, using the cell line models, we determined that MK-1775
enhanced araC-induced apoptosis, likely by enhancing S-phase DNA damage
caused by araC. These results support the further development of the wee1
inhibitor MK-1775 for the treatment of DS-AML.
4.2 Methods
4.2.1 Cell Lines, Culture Conditions, and Reagents
CMK cells were purchased from the German Collection of Microorganisms and
Cell Cultures (DSMZ; Braunschweig, Germany). The CMY cell line was a gift
from Dr. A. Fuse, (National Institute of Infectious Diseases, Tokyo, Japan). The
DS-AMKL cell lines CMK and CMY were both cultured in RPMI 1640 with 10%
FBS (Life Technologies, Carlsbad, CA, USA) and 2 mM L-glutamine plus 100
U/ml penicillin and 100 µg/ml streptomycin (Life Technologies), in a 37°C
humidified atmosphere containing 5% CO2/95% air. AraC was purchased from
Sigma (St. Louis, MO, USA) and MK-1775 was purchased from Selleck Chemical
(Houston, TX, USA). Diagnostic blast cells from DS children with AMKL (n=2)
were obtained from the Children’s Hospital of Michigan leukemia cell bank. Both
patients remain in first remission. Written consent was obtained according to the
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Declaration of Helsinki. The research protocol was approved by the Human
Investigation Committee of Wayne State University School of Medicine.
4.2.2 Antibodies
Rabbit antibodies directed against wee1, p-CDK1 (Y15), total CDK1, PARP,
phosphorylated histone H3(S10) (pH3) and γH2AX were purchased from Cell
Signaling Technologies (Danvers, MA, USA). Mouse anti-β-actin was purchased
from Sigma.

Goat anti-rabbit IRDye 800CW antibody for western blots was

purchased from Licor (Lincoln, NE, USA). Goat anti-rabbit-Alexa-488 for flow
cytometry was purchased from Life Technologies.
4.2.3 In Vitro Cytotoxicity Assay
Viable cells were determined using a standard 3-(4,5-dimethyl-2-thiazolyl)-2,5diphenyl-2H-tetrazolium bromide (MTT) assay as previously described[49].
Briefly, cells were added to a 96-well plate and cultured in the presence of
increasing drug concentrations for 72 hours. After 72 hours, MTT (Sigma, St.
Louis, MO, USA) was added to a final concentration of 1mM. After four hours,
formazan crystals were solubilized by addition of 10 mM HCl/10% sodium
dodecyl sulfate (SDS). Crystals were allowed to dissolve overnight and plates
were read using a microplate reader at 590 nm. For patient samples, 50,000
cells per well were cultured for 48 hours with ITS (Sigma) and conditioned media
(20% supernatant from 5637 bladder cancer cell line – a source of GM-CSF) in
the presence of various drug concentrations, after which MTT addition occurred
as above.

The presence or absence of synergistic drug interactions was

determined using the Compusyn software (Combosyn, Parasmus, NJ, USA)[27].
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Error bars represent standard error on the mean, determined from at least three
independent experiments.

When indicated, IC50s were compared using non-

parametric Mann-Whitney U test using GraphPad Prism 5 software (GraphPad
Software, La Jolla, CA, USA)
4.2.4 Lentiviral shRNA Knockdown of wee1 Expression
Lentivirus mediated gene expression knockdown was performed, as described
previously[224].

Lentivirus

shRNA

constructs

directed

against

WEE1

(designated sh-Wee1) or against no known gene (designated sh-NTC) were
purchased from Sigma. Mixed cultures expressing the shRNA of interest were
selected for by adding puromycin (Invivogen, San Diego, CA, USA) to the
standard culture media. Knockdown was confirmed by both quantitative reverse
transcription polymerase chain reaction (qRT-PCR) and western blot.
4.2.5 Western Blotting
Western blots were performed as previously described[35]. Briefly, cell lysates
were prepared in the presence of protease and phosphatase inhibitors (cOmplete
Mini and PhosStop, Roche, Indianapolis, IN, USA). Cell lysates were subjected
to SDS-PAGE and transferred to PVDF membranes (Pierce Scientific, Rockford,
IL, USA) for blotting with antibodies.
Odyssey scanner (Licor).

Membranes were scanned using an

Images are representative of at least 3 identical,

independent experiments.
4.2.6 qRT-PCR
qRT-PCR was performed as previously described[35]. Briefly, TaqMan probes
from Life Technologies (Carlsbad, CA, USA) directed against either WEE1 or

91

GAPDH mRNA were used for amplification and detection. Relative transcript
levels were determined using the delta-delta-CT method[117] and the experiment
was performed on a LightCycler 480 instrument (Roche, Indianapolis, IN, USA)
4.2.7 Flow Cytometry
Flow cytometry for apoptosis was performed using AnnexinV/Propidium iodide
(PI) dual staining, as described previously[225]. Analysis of γH2AX and pH3 vs
PI was performed using a protocol from Huang and Darzynkiewicz[82], with the
following modifications. One million cells per condition were spun at 300 rcf for 4
minutes and resuspended in 0.5 mL of 1% formaldehyde at 4°C for 15 minutes.
Samples were spun and resuspended in residual volume, followed by dropwise
addition of 1mL of ice-cold methanol and storage at 4°C for at least 30 minutes.
Samples were then processed according to protocol, using the antibody dilutions
recommended by the manufacturer with overnight primary incubation. Samples
were then counterstained with PI and analyzed as above.

Histograms were

analyzed with FlowJo (TreeStar Software, Ashland, OR, USA).

Images are

representative of at least 2 identical, independent experiments. Where indicated,
statistical analyses were performed using a paired t-Test.
4.3 Results
4.3.1 MK-1775 Has Single Agent Effect in DS-AML
To investigate the potential of targeting wee1 for the treatment of DS-AML,
two clinically relevant cell lines were used: CMK and CMY (which were derived
from a patient who initially responded to chemotherapy and a patient who had
refractory disease, respectively)[131,181]. Each cell line was originally derived
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from a pediatric DS patient with AMKL and a confirmed GATA1 mutation. As can
be seen in Figure 4.1A, CMK is much more sensitive (>50-fold) to araC than is
CMY. CMY was also significantly more resistant to ara-C-induced apoptosis as
measured by AnnexinV/PI staining by flow cytometry compared to the CMK line
(Figure

3D&E).

CMY

demonstrated

(using

clinically

achievable

drug

concentrations) class-wide resistance to both nucleoside analogues and
topoisomerase poisons (Table 4.1).

Interestingly, the cross resistance

demonstrated by CMY was not seen with MK-1775 (Figure 4.1B) with CMK and
CMY having IC50s of 291 and 316 nM, respectively (p=1.0). MK-1775 was able
to induce comparable, dose-dependent levels of apoptosis in both cell lines
(Figure 4.1C). Knockdown of wee1 expression using lentiviral delivery of shRNA
(Figure 4.1D&E) was able to further sensitize both cell lines to MK-1775,
suggesting that the effects of this drug are on-target.
4.3.2 Pharmacodynamic Changes of CDK1 Phosphorylation after Treatment
with MK-1775
Additional studies examined what dose schedule of MK-1775 would be the
most effective for combination treatments. CMK and CMY cells were treated with
increasing concentrations of MK-1775 for 24 hours, and phosphorylation status
of CDK1(Y15) was interrogated using western blots (Figure 4.2A&B). After 24
hour treatment, it was found that concentrations as low as 100 nM were able to
cause near-maximal inhibition of CDK1 phosphorylation.

To determine the

temporal kinetics of this inhibition, cells were treated with 100 nM MK-1775,
followed by drug washout (Figure 4.2A&B). Four hours of treatment was
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sufficient to decrease CDK1 (Y15) phosphorylation, but the effect was transient,
returning as soon as 1 hour post-drug washout. Based on these findings, it was
determined that simultaneous treatment would be utilized for further experiments.
4.3.3 MK-1775 Enhances the Cytotoxic Effects of AraC
The combination of MK-1775 with araC resulted in a synergistic reduction
in viable cells (Figure 4.3A&B), with CI values ranging from 0.57-0.74 and 0.70.77 for CMK and CMY, respectively (CI values <1 indicate synergism, =1
indicate additivity, and >1 indicate antagonism). Knockdown of wee1 was able to
enhance araC-induced cytotoxicity in both cell lines (Figure 4.3C). To investigate
whether MK-1775 could enhance araC-induced apoptosis, flow cytometry
analysis of AnnexinV/PI dual-staining was used. MK-1775 (100 nM) was able to
greatly enhance the apoptosis induced by araC in both cell lines (Figures
4.3D&E). Treatment of two diagnostic DS AMKL samples with varying doses of
araC and MK-1775 yielded synergistic inhibition of viable cells, with CIs ranging
from 0.28 to 0.65 (Figure 4.3F), confirming that these drug combinations could
ultimately be incorporated into clinical protocols.
4.3.4 MK-1775 Enhances AraC-induced DNA Damage in S-Phase
To begin elucidating the mechanism by which the combination of MK-1775
and araC-induced apoptosis, CMK and CMY cells were treated for 24 hours with
combinations of both agents and levels of pCDK1(Y15), PARP cleavage, and
γH2AX (a biomarker for DNA double strand breaks) were interrogated using
western blots. It is well-known that araC can cause replication stress, which
results in DNA damage and cell-cycle arrest through the ATR-CHK1
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pathway[177]. Therefore, it was important to determine whether MK-1775 could
abrogate the inhibition of CDK1 that results from activation of this checkpoint,
preventing cell cycle arrest. We hypothesized that MK-1775 would be able to
enhance araC-induced DNA damage as inhibition of wee1 alone can cause
replication stress, as well as inhibition of DNA repair. Indeed, MK-1775 was able
to abrogate the induction of pCDK1(Y15) and increase γH2AX induction by araC
in a dose-dependent fashion that paralleled the induction of apoptosis (measured
by PARP cleavage) (Figure 4.4).
There have been several reported mechanisms by which MK-1775 can
enhance the cytotoxicity of different chemotherapeutic agents including wee1
inhibition, which prevents activation of the G2/M DNA damage checkpoint,
allowing cells to progress aberrantly through the cell cycle and resulting in either
apoptosis or mitotic catastrophe. MK-1775 can also induce unscheduled mitosis,
which typically results in cell death. To assess for these mechanisms, cells were
treated with araC, MK-1775, or the combination for 24 hours and p-H3 (a marker
for mitosis) and γH2AX status were interrogated using flow cytometry. AraC
alone induced S-phase arrest, while MK-1775 alone had little impact on the cell
cycle profiles of CMY and CMK cells (Figures 4.5 and 4.6, respectively). While
the combination appeared to result in a slight rightward shift of the early-S peak
seen from araC alone, possibly indicating abrogation of an early-S arrest by MK1775, the most notable change seen in the combination treatment was the
significant increase in apoptosis as measured by cells with sub-G1 DNA content.
Additionally, it does appear that MK-1775 was able to decrease the amount of
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G2/M and S-phase after araC treatment in CMY and CMK, respectively (Figures
4.5-4.8). Though MK-1775 alone may have had a small impact on the number of
mitotic cells, (Figures 4.5 and 4.6), it did not appear to have caused the degree of
unscheduled mitoses reported previously in other cell types, and the modest
nature of these changes is unlikely to account for the amount of cell death seen.
Interestingly, MK-1775 was able to enhance araC-induced γH2AX primarily in Sphase in CMY cells (Figure 4.5). In CMK cells, the addition of MK-1775 to even
low concentrations of araC was able to primarily target cells in S-phase (Figure
4.6, 4.8), however it is unclear whether the increase in DNA damage shown in
Figure 4.4 occurred prior to or after the onset of apoptosis. It was expected that
if MK-1775 primarily enhanced araC-induced cell death by abrogation of G2/M
checkpoint, there would have been an increase in γH2AX+ cells in the G2/M
compartment.

The dearth of G2/M cells that stained positively for γH2AX

therefore is suggestive that the addition of MK-1775 to araC was able to cause
sufficient insult to cells that they simply underwent apoptosis directly from Sphase.
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Table 4.1 IC50s for nucleoside analogues and topoisomerase II poisons
IC50 (nM)
Drug
CMK
CMY
Clofarabine
14
350
Decitabine
50
1099
Daunorubicin
88
209
Etoposide
1251
4432
Mitoxantrone
12
69
* indicates p<0.05

Fold
25.0*
21.8*
2.4*
3.5*
5.8*

Figure 4.1 MK-1775 has single agent effect against DS-AML. A: AraC IC50s for CMK and
CMY after 72 hour treatment as determined by MTT. CMY is approximately 60-fold more
resistant to araC than CMK. B: CMK and CMY cells are comparably sensitive to MK-1775 as
determined by a 72-hour MTT assay. C: MK-1775 is able to induce comparable, albeit modest
dose-dependent apoptosis in both cell lines after 48-hour treatment, as determined by
AnnexinV/PI staining. D-E: Stable knockdown of wee1 using a lentivirus delivery system and
selection by puromycin resulted in reductions in wee1 levels as well as p-CDK(Y15) levels. F:
Knockdown of wee1 sensitized CMK and CMY cells to MK-1775, as determined by a 72-hour
MTT assay.
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Figure 4.2 Pharmacodynamic changes in p-CDK1(Y15) after MK-1775 treatment. Top:
CMK and CMY (A&B) cells were treated for 24 hours with increasing concentrations of MK-1775
and probed for CDK1(Y15) phosphorylation by western blot. Treatment for 24-hours with 100 nM
MK-1775 was able to cause near-maximal reduction of CDK1(Y15) phosphorylation in both CMK
and CMY. Bottom: CMK and CMY (A&B) cells were treated with 100 nM MK-1775 for 4 hours
followed by drug washout. Treatment with MK-1775 was able to inhibit CDK1 phosphorylation
after only four hours, but this phosphorylation returned after only 1 hour.
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Figure 4.3 MK-1775 synergizes with araC in both cell lines and primary patient samples.
A-B: CMK and CMY cells were treated with different combinations of araC and MK-1775 for 72hour and viability was determined by MTT assay.
Standard, normalized isobolograms
demonstrate the synergistic inhibition of cell viability by the combination of araC and MK-1775.
C: CMK and CMY –ntc and –shwee1 cells were treated for 72 hours with araC and viability was
determined by MTT. Knockdown of wee1 sensitized both cell lines to araC. D-E: CMK (D) and
CMY (E), were treated with varying doses of araC in the presence or absence of 100 nM MK1775 for 48 hours and apoptosis was measured using AnnexinV/PI staining. F: Various
combinations of araC and MK-1775 were tested in 2 primary DS-AML samples ex vivo using 48hour MTT. The CI-Fa plot shows the combination index vs. the fraction affected, with CI < 1
representing synergy.
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Figure 4.4 MK-1775 can abrogate araC-induced CDK1(Y15) phosphorylation and enhance
araC-induced DNA damage. CMK and CMY cells were treated for 24 hours with the indicated
drugs.
MK-1775 was able to, in a dose dependent fashion, decrease CDK1(Y15)
phosphorylation and increase araC-induced DNA damage (γH2AX) and apoptosis (PARP
cleavage).
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Figure 4.5 MK-1775 effects on cell cycle, mitosis, and DNA damage. CMY cells were treated
with the indicated drug for 24 hours and analyzed by flow cytometry. Top: The effects of araC
and MK-1775 on cell cycle were determined using PI staining. Middle: The effects of araC and
MK-1775 on mitosis vs. cell cycle were determined using dual pH3/PI staining. Bottom: The
effects of araC and MK-1775 on DNA damage vs cell cycle were determined using dual
γH2AX/PI staining. * indicates p<0.05 compared to araC treatment.

101

Figure 4.6 MK-1775 effects on cell cycle, mitosis, and DNA damage. CMK cells were treated
with the indicated drug for 24 hours and analyzed by flow cytometry. Top: The effects of araC
and MK-1775 on cell cycle were determined using PI staining. * indicates p<0.05 compared to
araC treatment. Middle: The effects of araC and MK-1775 on mitosis vs. cell cycle were
determined using dual pH3/PI staining. Bottom: The effects of araC and MK-1775 on DNA
damage vs cell cycle were determined using dual γH2AX/PI staining.
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Figure 4.7 MK-1775 can decrease G2/M fraction of viable CMY cells, especially at higher
doses. CMY cells were treated with the indicated drug for 24 hours and analyzed by flow
cytometry using PI staining. Non-viable (sub-G1) cells were gated out to facilitate analysis of
viable cell cycle profile, as higher MK-1775 doses (300 and 400 nM) in the combination treatment
resulted sub-G1 populations >50%, obfuscating cell-cycle changes. * indicates p<0.05
compared to araC treatment.
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Figure 4.8 CMK cells treated with the combination of araC and lower doses of MK-1775
appear to die out of S-phase. CMK cells were treated with the indicated drug for 24 hours and
analyzed by flow cytometry using dual γH2AX/PI staining. The left panel for each treatment
shows the two-dimensional histogram while the right panel shows the cell cycle analysis using
only PI staining.
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Figure 4.9 Schematic of MK-1775 and araC effects on cell survival. A: In the absence of
either drug, wee1 inhibits CDK1 by phosphorylation at Y15. Cdc25 phosphatases constitutively
remove this phosphorylation, with the net result being cell growth and survival. B: When araC is
present, it can incorporate into newly synthesized DNA, causing chain termination and
subsequent DNA damage and checkpoint activation. This inactivates cdc25 phosphatases, with
the result being cell cycle arrest. In some cells, this leads to cell death, however most cells are
able to repair the damage and survive. C: In the presence of MK-1775, wee1 cannot inhibit
CDK1, so it remains active and DNA replication occurs unimpeded. Unregulated replication
results in some DNA damage and cell death due to lack of necessary cofactors and inability to
activate cell cycle checkpoints, but the net result is largely cell survival. D: In the presence of
both drugs, replication continues despite DNA damage induced by araC. The inhibition of wee1
by MK-1775 makes cell cycle checkpoint activation irrelevant. AraC continues to incorporate into
newly firing replication forks, resulting in large amounts of DNA damage. The result is then
primarily cell death by apoptosis.
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4.4 Discussion
DS children with AML have an overall very favorable prognosis with eventfree survival rates of ~80%[223]. However, for patients with either refractory or
relapsed disease, the prognosis is very poor highlighting the need to develop
new effective therapeutic options. Targeting the wee1 kinase for treatment of
malignancy is rapidly emerging with several phase 1 or phase 2 clinical trials
currently underway (www.clinicaltrials.gov), including one pediatric brain tumor
trial. In our study, we provide strong evidence to support the further development
of combining the wee1 inhibitor MK-1775 with araC for the treatment of DS-AML.
Early published results from phase 1 trials have indicated that the maximal
plasma concentration of MK-1775 is approximately 400-500 nM, with an oral
twice daily dosing regimen for 5 doses [108,206]. Though single-agent activity of
MK-1775 at those levels appears to be modest, the concentrations used in this
study (100-200 nM) for combination studies are well below that threshold.
Therefore, even if substantial dose reductions are necessary in this population,
our findings are likely to have clinical relevance. Furthermore, based on the
results from Figure 4.2 suggesting that araC and MK-1775 should likely be dosed
simultaneously, the MK-1775 dosing strategy used previously is likely compatible
with the 4-day infusion schedule for araC used in the most recent DS-AML
clinical trial, Children’s Oncology Group AAML0431. Although this study lacks in
vivo toxicity and efficacy data, a recently published study using a murine AML
model found that the toxicity of the combination was similar to that of araC
alone[208].
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Most of the prior studies investigating MK-1775 focused on its ability to
abrogate a G2/M cell cycle checkpoint to enhance cell death. It was initially
reported that this response was only effective in p53-mutant cells, though that
notion has been challenged and may represent a cancer- or cell-type-specific
phenomenon[1,15,23,60,69,70,99,160,208]. While similar results were expected
in our study, it was surprising to see that G2/M checkpoint abrogation did not
seem to contribute substantially to the cytotoxic effect of the combination of MK1775 and araC, and instead cells were likely dying in S-phase (Figures 4.5-4.8).
Although it would be ideal if MK-1775 synergizes with anthracycline
chemotherapy, the lack of substantial G2/M arrest abrogation, and unfavorable
previously published results[208] suggest that this is likely not the case.

It is

important to note that these findings do not contradict those seen in previous
studies (G2/M abrogation, unscheduled mitosis), given that those studies were
performed using mostly solid tumor lines.

Instead, our results agree with a

recently published study that suggests MK-1775 is able to abrogate an intra-S
checkpoint[208]. With this in mind, we propose a model (illustrated in Figure 4.9)
in which wee1 inhibition by MK-1775 prevents activation of the S-phase
checkpoint normally activated by araC. Subsequently, replication forks continue
to fire [8,9], allowing for more araC incorporation and subsequent fork collapse.
Eventually, a catastrophic level of DNA damage is sustained, and the cell
undergoes apoptosis without completing DNA replication. Though further work is
necessary to fully confirm this hypothesis, if true, it could have important
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implications for the combination of MK-1775 with nucleoside analogues that rely
on DNA synthesis for anti-tumor effect.
As a whole, the data presented here support the further development of
MK-1775 as a potential adjuvant to araC for the treatment of DS-AML. MK-1775
is able to greatly enhance the anti-leukemic effects of araC, primarily by
enhancing araC’s DNA damaging effect in S-phase. The anti-leukemic effect was
independent of sensitivity to araC alone, and was validated ex vivo using primary
DS-AML blasts. Based on our results, MK-1775 appears to be an exciting new
option for the treatment of relapsed or refractory DS-AML and for further clinical
trial development which may also be relevant to non-DS AML patients as well.
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CHAPTER 5 – Discussion and Future Directions
Despite great advances in the treatment of AML, it remains deadly for
many of the children affected by this disease. Fortunately, by utilizing carefully
designed clinical trials and conducting relevant bench research, advances in the
treatment of these patients will continue to be made.
Previous studies on the biology of DS-AML blasts found that, at least
partially as a result of modulated GATA1 function, these blasts were more
sensitive to chemotherapy [51,53,201-203].

The finding that lower GATA1

activity in DS-AML blasts positively impacts outcome for those patients led to the
hypothesis that higher GATA1 activity in non-DS AMKL cases may have the
opposite effect. Indeed, as the results in Chapter 2 of this work show, this turned
out to be the case. GATA1 was overexpressed in AML cases of the AMKL
phenotype compared to non-AMKL cases, and knockdown of GATA1 in a
megakaryocytic AML cell line was found to enhance sensitivity to both araC and
DNR. One mechanism by which GATA1 conveys chemotherapy resistance is
that GATA1 affects the expression of the anti-apoptotic Bcl-2 family protein BclxL. Furthermore, it was shown that treatment with the HDAC inhibitor VPA was
able to down-regulate both GATA1 and Bcl-xL sensitizing cells to treatment with
araC.
In addition to the additional GATA1 target genes identified for future study,
the results in Chapter 2 have potential therapeutic implications. In the non-DS
AML population, the AMKL subtype is considered to be high risk with a relatively
poor prognosis (EFS < 35%) [5,140,173]; therefore novel therapies that may be
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especially useful in this patient group are of interest. Since the completion of the
work presented in Chapter 2, novel HDAC inhibitors have been developed
clinically, such as panobinostat and vorinostat (reviewed in[134,155]). With new
agents, it may be possible to target mechanisms of resistance including
overexpression of GATA1, even though such targets had previously been
considered “undruggable.” Additionally, the confirmation of Bcl-xL as contributing
to the resistance in AMKL offers another potential avenue for therapeutic
intervention. There has been great interest in targeting the anti-apoptotic Bcl-2
family proteins in recent years, as inhibition of these proteins has been shown to
be effective in a variety of malignancies[33,139]. It does merit note, however,
that this excitement is somewhat tempered by the finding that inhibition of Bcl-xL
may lead to thrombocytopenia[168,221], highlighting the benefit vs. risk balance
which must be considered when developing new cancer therapies.
With regard to DS-AML, the important findings presented in this work
include the identification of wee1 inhibition by MK-1775 as an attractive option for
further pre-clinical and clinical development. Despite the otherwise promising
compounds in Chapter 3 not being as effective as hoped, the results from the
MK-1775 are encouraging.

As a single agent, MK-1775 demonstrated

comparable effects in both the CMK and CMY cell lines, albeit at concentrations
toward the high end of what is clinically achievable. However, in combination
with araC, MK-1775 was able to enhance the inhibitory effect of araC in a
synergistic fashion.

Importantly, from the results presented in Chapter 4, it

appears that MK-1775 exerts its effects on CMK and CMY cells primarily in S-
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phase, a finding that was largely unexpected, as previous studies had largely
suggested that inhibiting wee1 targets cells in G2 [1,15,23,60,69,70,99,160,208].
The role of wee1 in human cells is to maintain inhibitory phosphorylation
on CDK1 and CDK2 such that CDK activity is controlled appropriately according
to the phase of the cell cycle. Though initial studies of MK-1775 were focused on
a G2-phase effect, the results presented here, especially in combination with
work from other groups, suggest that there is an important role for MK-1775 in
the targeting of S-phase cell cycle control [153,208]. Moving forward, it will be
important to further clarify the mechanism by which MK-1775 exerts these effects
so that its maximal therapeutic potential may be realized.
From previous studies, it is clear that there is a role for CDK1 in the
control of S-phase regulation. It has been shown that forced activation of CDK1
by inhibition or knockdown of wee1 causes S-phase DNA damage, as well as
increased replication fork firing and decreased fork length[8,9]. Furthermore, it
was shown that the shorter fork lengths were thought to be caused by an
insufficient supply of necessary cofactors, a phenotype which was partly
reversed by adding exogenous nucleosides[8].

This potentially offers

mechanistic insight into the recent findings that MK-1775 was able to enhance
sensitivity to pemetrexed, an antifolate that reduces available nucleoside
pools[208]. If the effect of MK-1775 treatment really is predominantly in the Sphase, it would be expected that it would synergize better with agents that act in
S-phase (and activate S-phase DNA damage checkpoints) than agents that act
in G2 (activating G2/M DNA damage checkpoints). This is indeed the case, at
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least for CMK and CMY cells (Figure 5.1). It was found that for both cell lines,
the combination with MK-1775 demonstrated greater synergy with the nucleoside
analogues araC, decitabine, and clofarabine, than it did with the Topo2 poisons
DNR, VP16, and the mitotic inhibitor vincristine (VCR).
Another question regarding the activity of MK-1775 is whether or not it
primarily exerts its effect on CDK1 or CDK2.

Traditionally, CDK1 has been

considered to be the CDK responsible for driving mitosis, while CDK2 drives
DNA replication.

This notion was challenged, however, when it was

demonstrated that not only can CDK1 perform the roles of CDK2[4], but CDK1 is
capable of compensating for CDKs 2,3,4, and 6. In fact, those kinases are all
dispensable, but the roles of CDK1 cannot be performed by its family members
and CDK1 knockout produces non-viable embryos[180]. Importantly, wee1 is
capable of regulating CDK2 as well as CDK1, as the two proteins share
homologous N-termini, which include the regulatory tyrosine 15[28,59]. In fact, a
constitutively active CDK2 knock-in mutant reproduced many of the phenotypes
seen in wee1 depleted cells[85].

Furthermore, pan-CDK inhibition with

Roscovitine was able to antagonize the MK-1775 effect more than was specific
CDK1 inhibition with RO-3306 in CMK and CMY cells (Figure 5.2). It will be
important to use more specific approaches to further assess these differences in
the future.
Though these differences in potential mechanisms of action may seem
insignificant at first, given the similar phenotypes expected, determining the
major mechanisms at play is still important.

First, better understanding the
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mechanism by which wee1 inhibition enhances araC-induced apoptosis of AML
cells allows for better treatment design.

It also allows for the potential

identification of new drug targets that are in the affected pathway, which might
have fewer side effects. Finally, and perhaps most importantly in the short-term,
if treatment with MK-1775 predominantly affects S-phase arrest, agents that
target S-phase cells should be preferentially combined with MK-1775 in clinical
trials.
In conclusion, the work presented in this dissertation describes preclinical
efforts at improving outcomes for pediatric AML patients in both the DS and the
non-DS populations.

The findings presented in Chapter 2 demonstrate a

potential for using novel therapies, like HDAC or Bcl-2 family inhibitors to treat
AMKL, as well as offering insight into the mechanisms of resistance in a difficult
to treat disease.

Those findings presented in Chapters 3 and 4 lay the

foundation for the use of MK-1775 to enhance the effects of araC in DS-AML.
Though there is always more to be elucidated, the studies described herein set
the stage for such further work, with the eventual goal of improving outcomes for
pediatric AML.
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Figure 5.1 Isobolograms and CIs for the combination of MK-1775 with various cell-cyclespecific agents. Construction of isobolograms and CI plots as performed as in Chapter 3. CMK
and CMY cells were treated for three days in the presence of increasing concentrations of the
indicated drug with or without increasing concentrations of MK-1775 for 72 hours and analyzed
using standard MTT assay. TOP: MK-1775 was combined with either DNR, VP16, or VCR (lefttop) and either decitabine, clofarabine, or araC (right-top).
BOTTOM: The CIs from the top
panel were segregated by cell line and by whether the non-MK-1775 agent targets S- or G2/Mphase cells. Within each cell line, G2/M and S groups were found to be significantly different
using the non-parametric Kruskal-Wallis test with Dunn’s post-test correction (*). When the cell
lines are combined, the G2/M values are significantly different than S values (p<0.0001) using the
non-parametric Mann-Whitney U test (†).
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Figure 5.2 Isobolograms and CIs for the combination of MK-1775 and either Roscovitine
or RO-3306 in CMK and CMY cells. Construction of isobolograms and CI plots was performed
as in Chapter 3. CMK and CMY cells were treated for three days in the presence of increasing
concentrations of MK-1775 with or without increasing concentrations of either Roscovitine or RO3306 and for 72 hours and analyzed using standard MTT assay. Note that the scale for the
roscovitine isobolograms and CI plot is much larger than in previous figures.
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ABSTRACT
IDENTIFYING MECHANISMS OF RESISTANCE AND POTENTIAL
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Acute myeloid leukemia (AML) is a potentially devastating disease that
can affect people of all ages. While there are certain patient groups that typically
have favorable outcomes, in the pediatric population, overall survival (OS) is
approximately 70%, leaving much progress to be made. Children with Down
syndrome (DS) have a substantially elevated risk for developing AML, especially
of the megakaryocytic phenotype (AMKL).
Patients with DS AMKL almost universally harbor a mutation in the gene
encoding the GATA1 transcription factor, resulting in the translation of a shortform protein GATA1s, which has been shown to contribute to chemotherapy
sensitivity. In contrast, in non-DS patients, overexpression of GATA1 has been
correlated with poorer outcomes. In the first half of this work, we investigated the
role that elevated GATA1 expression plays on the sensitivity of AMKL cells to
chemotherapy. To begin, we confirmed that amongst non-DS patients, GATA1
transcripts were significantly higher in AMKL blasts compared to blasts from
other AML subgroups. Further, GATA1 transcript levels significantly correlated
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with transcript levels for the anti-apoptotic protein Bcl-xL in our patient cohort.
We demonstrated that Bcl-xL is a GATA1 target, and knockdown of GATA1 with
shRNA sensitizes cells to chemotherapy treatment and decreases Bcl-xL
expression. Treatment of Meg-01 cells with the histone deacetylase inhibitor
valproic acid resulted in down-regulation of both GATA1 and Bcl-xL and
significantly enhanced ara-C sensitivity. Furthermore, additional GATA1 target
genes were identified by oligonucleotide microarray and ChIP-on-Chip analyses.
While OS for DS AML is generally very favorable (approximately 90%), DS
patients with refractory or relapsed disease have dismal prognoses, with OS in
that group only approximately 25%.

Therefore, there is a need for the

development of new therapeutic approaches for these patients. In the second
half of this work, we investigated the response of 2 DS AML cell lines, CMK and
CMY, to the combination of araC and one of either the aurora A kinase inhibitor
MLN8237, the aurora B kinase inhibitor AZD1152-HQPA, the Plk1 inhibitor
BI6237, or the wee1 inhibitor MK-1775. It was found that MK-1775, in contrast to
the other three agents, synergized with araC in antiproliferative MTT assays in
both cell lines as well as in ex vivo DS-AML primary patient samples. MK-1775
was able to decrease inhibitory CDK1(Y15) phosphorylation after only 4 hours,
and was able to enhance araC-induced DNA damage in S-phase and partially
abrogate araC-induced cell cycle arrest.
The work presented in this dissertation describes preclinical efforts at
improving outcomes for pediatric AML patients in both the DS and the non-DS
populations.

The findings presented demonstrate a potential for using novel
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therapies, including HDAC or Bcl-2 family inhibitors to treat AMKL, as well as
offering insight into the mechanisms of resistance in a difficult to treat disease.
Furthermore, these findings lay the foundation for the use of MK-1775 to
enhance the effects of araC in DS-AML. Though there is always more to be
elucidated, the studies described herein set the stage for such further work, with
the eventual goal of improving outcomes for pediatric AML.
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